US20210355193A1 - Monoclonal anitbody for spike protein of middle east respiratory syndrome coronavirus and use thereof - Google Patents
Monoclonal anitbody for spike protein of middle east respiratory syndrome coronavirus and use thereof Download PDFInfo
- Publication number
- US20210355193A1 US20210355193A1 US16/641,580 US201816641580A US2021355193A1 US 20210355193 A1 US20210355193 A1 US 20210355193A1 US 201816641580 A US201816641580 A US 201816641580A US 2021355193 A1 US2021355193 A1 US 2021355193A1
- Authority
- US
- United States
- Prior art keywords
- seq
- mers
- chain variable
- variable region
- cov
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 title claims abstract description 103
- 229940096437 Protein S Drugs 0.000 title claims abstract description 65
- 101710198474 Spike protein Proteins 0.000 title claims abstract description 65
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims abstract description 66
- 239000000427 antigen Substances 0.000 claims abstract description 43
- 102000036639 antigens Human genes 0.000 claims abstract description 43
- 108091007433 antigens Proteins 0.000 claims abstract description 43
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 64
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 51
- 150000001413 amino acids Chemical class 0.000 claims description 46
- 239000013598 vector Substances 0.000 claims description 42
- 238000001514 detection method Methods 0.000 claims description 34
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 238000011002 quantification Methods 0.000 claims description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 abstract description 64
- 230000003472 neutralizing effect Effects 0.000 abstract description 34
- 102000004169 proteins and genes Human genes 0.000 abstract description 21
- 241001112090 Pseudovirus Species 0.000 abstract description 14
- 210000004027 cell Anatomy 0.000 description 50
- 239000000203 mixture Substances 0.000 description 31
- 239000003814 drug Substances 0.000 description 30
- 239000003550 marker Substances 0.000 description 28
- 239000000463 material Substances 0.000 description 25
- 229940079593 drug Drugs 0.000 description 24
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 23
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 108010008595 sarcoma-associated antigen S1 Proteins 0.000 description 15
- 241000700605 Viruses Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 238000003745 diagnosis Methods 0.000 description 13
- 230000002265 prevention Effects 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000002285 radioactive effect Effects 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- -1 aminoglycoside Chemical class 0.000 description 9
- 238000011278 co-treatment Methods 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 210000003527 eukaryotic cell Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 229940127121 immunoconjugate Drugs 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000011835 investigation Methods 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 239000011859 microparticle Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000013638 trimer Substances 0.000 description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 206010036790 Productive cough Diseases 0.000 description 6
- 230000001919 adrenal effect Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 210000001508 eye Anatomy 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 238000013537 high throughput screening Methods 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 210000003928 nasal cavity Anatomy 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 238000007911 parenteral administration Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000001817 pituitary effect Effects 0.000 description 6
- 210000002826 placenta Anatomy 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 210000003079 salivary gland Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 210000003802 sputum Anatomy 0.000 description 6
- 208000024794 sputum Diseases 0.000 description 6
- 238000001847 surface plasmon resonance imaging Methods 0.000 description 6
- 210000001685 thyroid gland Anatomy 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 101100503323 Artemisia annua FPS1 gene Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 101100503326 Gibberella fujikuroi FPPS gene Proteins 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical class O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 4
- 102000012440 Acetylcholinesterase Human genes 0.000 description 4
- 108010022752 Acetylcholinesterase Proteins 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 229940022698 acetylcholinesterase Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000004057 biotinyl group Chemical class [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000013522 chelant Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000002848 electrochemical method Methods 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 108010073233 gamma-lactamase Proteins 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000003345 scintillation counting Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 238000002849 thermal shift Methods 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000002795 fluorescence method Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 238000000053 physical method Methods 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 102000044437 S1 domains Human genes 0.000 description 2
- 108700036684 S1 domains Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000005727 virus proliferation Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 241000228257 Aspergillus sp. Species 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241001037822 Bacillus bacterium Species 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 241000008904 Betacoronavirus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710104662 Enterotoxin type C-3 Proteins 0.000 description 1
- 241000488157 Escherichia sp. Species 0.000 description 1
- 102100030844 Exocyst complex component 1 Human genes 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101900332836 Middle East respiratory syndrome-related coronavirus Nucleoprotein Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000088436 Neurospora sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000235061 Pichia sp. Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000334216 Proteus sp. Species 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000235088 Saccharomyces sp. Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000720795 Schizosaccharomyces sp. Species 0.000 description 1
- 241001147693 Staphylococcus sp. Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187180 Streptomyces sp. Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000723873 Tobacco mosaic virus Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 102000045598 human DPP4 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- VQOXZBDYSJBXMA-RKEBNKJGSA-N nystatin a1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@@H]1OC1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)CC(O)CC(O)CC(O)CCC(O)C(O)C[C@](O)(CC(O)C2C(O)=O)OC2C1 VQOXZBDYSJBXMA-RKEBNKJGSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000013379 physicochemical characterization Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 239000013639 protein trimer Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical compound NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Definitions
- the present invention relates to monoclonal antibodies for a spike protein of Middle East respiratory syndrome coronavirus and a use thereof.
- Middle East respiratory syndrome was first identified in the Middle East region in September 2012. According to the report made by WHO, MERS spread to 26 countries as of Jun. 5, 2017, resulting in 1,980 confirmed patients and 693 deaths worldwide. It is a high-risk disease with a mortality rate of 35%.
- MERS-CoV Middle East respiratory syndrome coronavirus
- YCoV beta-coronavirus
- SARS severe acute respiratory syndrome virus
- MERS-CoV penetrates into cells as being conjugated with a human DPP4 (dipeptidyl peptidase 4) receptor by using a spike protein (S protein) (Wang N, Shi X, Jiang L J, Zhang S, Wang D, Tong P, Guo D, et al., Cell Research. 2013:23:986).
- S protein spike protein
- Interferon is an immune protein released when a virus or germ enters in a human body, inducing the surrounding cells to emit antiviral cytokines, inhibiting virus proliferation, and inviting immune cells to remove the virus-infected cells.
- interferon can cause side effects such as bone marrow suppression, anemia, decrease of white cell number, or decrease of platelet number.
- Ribarvirin the antiviral agent, inhibits the proliferation of various types of viruses by interrupting the RNA synthesis thereof in the form of a nucleoside analogue.
- ribarvirin also induces side effects such as toxicity, carcinogenesis, or hemolytic anemia.
- the administration of interferon and ribarvirin for the treatment of MERS has not been supported by the clinical tests. In the rhesus monkey animal model, the co-administration of interferon and ribarvirin was effective in treating MERS (Falzarano D, Wit E, Rasmussen A L., et al., Nature Medicine, 2013, 19, 10, p 1313-1318).
- Korean Patent No 10-1593641 describes a monoclonal antibody binding specifically to MERS-CoV nucleocapsid and a composition for diagnosing MERS-CoV comprising the same.
- the present inventors tried to develop therapeutic antibodies for MERS-CoV.
- the inventors succeeded in preparation of 24 kinds of monoclonal antibodies specifically binding to the spike protein of MERS-CoV.
- the inventors further confirmed that 11 antibodies (77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1, and 90-F2) among them had excellent adhesion to MERS-CoV full-length spike and S1 antigen, and 90-F1, 90-E5, 90-E6, 90-F2, 77-A5, and 77-A6 antibodies demonstrated excellent adhesion to MERS-CoV RBD antigen.
- 77-A5, 77-A6, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies showed neutralizing ability against MERS pseudovirus and MERS-CoV
- 90-B2 and 90-B7 antibodies showed neutralizing ability only against MERS-CoV.
- the present inventors further confirmed that the antibodies of the present invention are in the form of a certain monomer and have excellent physical stability, leading to the completion of the present invention.
- the present invention provides a heavy chain variable region of the monoclonal antibody specifically binding to the MERS-CoV spike protein whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21.
- CDR complementarity determining region
- the present invention also provides a gene encoding the heavy chain variable region of the monoclonal antibody of the invention.
- the present invention also provides a recombinant vector comprising the gene encoding the heavy chain variable region of the monoclonal antibody of the invention.
- the present invention also provides a host cell introduced with the gene encoding the heavy chain variable region of the monoclonal antibody of the invention or the recombinant vector comprising the gene above.
- the present invention also provides a composition for the prevention, treatment or diagnosis of Middle East respiratory syndrome comprising the heavy chain variable region of the monoclonal antibody of the invention.
- the present invention also provides a kit for the detection or quantification of an antigen of Middle East respiratory syndrome comprising the heavy chain variable region of the monoclonal antibody of the invention.
- the present invention also provides a light chain variable region of the monoclonal antibody specifically binding to the MERS-CoV spike protein whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- CDR complementarity determining region
- the present invention also provides a gene encoding the light chain variable region of the monoclonal antibody of the invention.
- the present invention also provides a recombinant vector comprising the gene encoding the light chain variable region of the monoclonal antibody of the invention.
- the present invention also provides a host cell introduced with the gene encoding the light chain variable region of the monoclonal antibody of the invention or the recombinant vector comprising the gene above.
- the present invention also provides a composition for the prevention, treatment or diagnosis of Middle East respiratory syndrome comprising the light chain variable region of the monoclonal antibody of the invention.
- the present invention also provides a kit for the detection or quantification of an antigen of Middle East respiratory syndrome comprising the light chain variable region of the monoclonal antibody of the invention.
- the present invention also provides a monoclonal antibody specifically binding to the MERS-CoV spike protein containing a heavy chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21, and a light chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- the present invention also provides a gene encoding the monoclonal antibody of the invention.
- the present invention also provides a recombinant vector containing the gene encoding the monoclonal antibody of the invention.
- the present invention also provides a host cell introduced with the gene encoding the monoclonal antibody of the invention or the recombinant vector comprising the gene above.
- the present invention also provides a composition for the prevention, treatment or diagnosis of Middle East respiratory syndrome comprising the monoclonal antibody of the invention.
- the present invention provides a kit for the detection or quantification of an antigen of Middle East respiratory syndrome comprising the monoclonal antibody of the invention.
- the present invention also provides a method for preventing, treating or diagnosing Middle East respiratory syndrome comprising a step of administering the heavy chain variable region of the monoclonal antibody of the invention to a subject.
- the present invention also provides a use of the heavy chain variable region of the monoclonal antibody of the invention for the manufacture of a medicament for preventing, treating or diagnosing Middle East respiratory syndrome.
- the present invention also provides a method for preventing, treating or diagnosing Middle East respiratory syndrome comprising a step of administering the light chain variable region of the monoclonal antibody of the invention to a subject.
- the present invention also provides a use of the light chain variable region of the monoclonal antibody of the invention for the manufacture of a medicament for preventing, treating or diagnosing Middle East respiratory syndrome.
- the present invention also provides a method for preventing, treating or diagnosing Middle East respiratory syndrome comprising a step of administering the monoclonal antibody of the invention to a subject.
- the present invention provides a use of the monoclonal antibody of the invention for the manufacture of a medicament for preventing, treating or diagnosing Middle East respiratory syndrome.
- Monoclonal antibodies 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1 and 90-F2 according to the present invention have excellent attachment force with respect to a full-length spike protein of MERS-CoV and the S1 domain of the protein, and, of the monoclonal antibodies, the monoclonal antibodies 90-F1, 90-E5, 90-E6, 90-F2, 77-A5 and 77-A6 have excellent attachment force with respect to an RBD antigen of MERS-CoV.
- the antibodies 77-A5, 77-A6, 90-E5, 90-E6, 90-F1 and 90-F2 exhibit neutralizing capacity with respect to a MERS pseudovirus and MERS-CoV
- the antibodies 90-B2 and 90-B7 exhibit neutralizing capacity only with respect to MERS-CoV.
- the monoclonal antibodies have a particular monomeric form, and have excellent stability and thus may be useful for treating or diagnosing MERS.
- FIG. 1 is a graph illustrating the adhesion of 77-A1, 77-A4, 77-A5, 77-A6, 77-A9, 77-A10, 77-A11, 77-A12, 77-B3, 77-B4, 77-B12, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-C5, 90-D6, 90-E1, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies to the full-length spike trimer antigen of MERS-CoV.
- C2, A2, A10, G2, and G4 antibodies developed by NIH, USA were used as the positive controls.
- FIG. 2 is a graph illustrating the adhesion of the antibodies above to the MERS-CoV S1 antigen composed of the amino acids 1 to 757 of the spike protein.
- FIG. 3 is a graph illustrating the adhesion of the antibodies above to the MERS-CoV RBD antigen composed of the amino acids 377 to 588 of the spike protein.
- FIG. 4 is a graph illustrating the adhesion of the antibodies above to the MERS-CoV S2 antigen composed of the amino acids 757 to 1275 of the spike protein.
- FIG. 5 a is a set of graphs illustrating the neutralizing ability of 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies against pseudovirus using the spike protein of MERS-CoV Erasmus strain.
- FIG. 5 b is a set of graphs illustrating the neutralizing ability of 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies against pseudovirus using the spike protein of MERS-CoV Bisha 1 strain.
- FIG. 6 a is a set of graphs illustrating the neutralizing ability of 77-A5, 77-A6, 90-A3, 90-A9, 90-B2 and 90-B7 antibodies against MERS-CoV.
- FIG. 6 b is a set of graphs illustrating the neutralizing ability of 90-C4, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies against MERS-CoV.
- FIG. 7 is a graph illustrating the morphology of the antibodies analyzed by SEC-HPLC.
- FIG. 8 a is a set graphs illustrating the antigen-antibody binding affinity investigated by SPR (Surface Plasmon Resonance) assay using S1 antigen.
- FIG. 8 b is a set graphs illustrating the antigen-antibody binding affinity investigated by SPR (Surface Plasmon Resonance) assay using RBD antigen.
- FIG. 9 a is a set of graphs illustrating the thermo-stability of 77-A5 and 77-A6 antibodies investigated by PTS (Protein Thermal Shift) assay.
- FIG. 9 b is a set of graphs illustrating the thermo-stability of 90-B2 and 90-B7 antibodies investigated by PTS (Protein Thermal Shift) assay.
- FIG. 9 c is a set of graphs illustrating the thermo-stability of 90-F1, and 90-F2 antibodies investigated by PTS (Protein Thermal Shift) assay.
- the present invention provides a heavy chain variable region of the monoclonal antibody binding specifically to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21.
- CDR complementarity determining region
- the spike protein above can be a polypeptide composed of any sequence known to those in the art.
- the polypeptide above can be a variant or a fragment of an amino acid sequence having a different sequence made by deletion, insertion, substitution or combination thereof as long as it does not affect the protein function.
- the exchange of amino acids in a protein or a peptide, without changing the overall molecular activity, has been well-informed to those in the art.
- the spike protein can be composed of the amino acid sequence represented by SEQ. ID. NO: 23.
- the said heavy chain variable region can specifically bind to the 1 st to 757 th amino acid sites from the N-terminus of the spike protein of MERS-CoV.
- the heavy chain variable region of the monoclonal antibody whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 15, 17, 19, or NO: 21 can bind specifically to the 377 th to 588 th amino acid sites from the N-terminus of the spike protein of MERS-CoV.
- the present inventors prepared 24 kinds of monoclonal antibodies binding specifically to the spike protein of MERS-CoV.
- 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies were confirmed to have excellent adhesion to the full-length spike protein and S1 antigen of MERS-CoV (see FIGS. 1 and 2 ).
- 90-F1, 90-E5, 90-E6, 90-F2, 77-A5, and 77-A6 antibodies were confirmed to have excellent adhesion to the RBD antigen of MERS-CoV (see FIG. 3 ).
- the present invention also provides a gene encoding the heavy chain variable region of the monoclonal antibody; a recombinant vector containing the gene above; and a host cell introduced with the gene or the recombinant vector above.
- the heavy chain variable region above can be characterized by the description above.
- the heavy chain variable region can be the heavy chain variable region of the monoclonal antibody binding specifically to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21.
- CDR complementarity determining region
- the gene above includes not only a sequence encoding the heavy chain variable region but also a polynucleotide having the same nucleotide sequence substantially identical to the gene and a fragment thereof.
- the polynucleotide having the same nucleotide sequence substantially identical to the gene can have at least 80%, preferably 90% s, and more preferably at least 95% homology with the polypeptide of the present invention.
- the polynucleotide of the present invention can include a variant in which one or more nucleotide sequences are substituted, deleted or inserted, as long as the variant encode a protein having the equivalent activity.
- the said vector is a recombinant vector capable of expressing a target peptide in a desired host cell, which indicates a gene construct containing a necessary regulatory element operably linked thereto in order to express the gene insert.
- the vector includes such expression regulatory elements as initiation codon, termination codon, promoter, and operator, etc.
- the initiation codon and termination codon are generally considered as a part of the nucleotide encoding a polypeptide and they have to be in frame with the coding sequence so as to be functioning in a subject when the gene construct is inserted.
- operably linked indicates a state in which a nucleic acid expression control sequence and a nucleic acid sequence encoding a target protein or RNA are functionally linked to perform a general function.
- a promoter can be operably linked to a nucleic acid sequence encoding a protein or RNA, which affects the expression of the coding sequence.
- the operable linkage can be achieved by using the genetic recombination technique which is well-known to those in the art.
- the site-specific DNA cleavage and linkage can be accomplished by using the enzyme well known to those in the art.
- the vector system of the present invention can be constructed through various methods known to those in the art, and a specific method for this is disclosed in “Sambrook, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001)”.
- the vector of the present invention can be constructed as a typical cloning vector or an expression vector.
- the vector of the present invention can be constructed by using a prokaryotic cell or a eukaryotic cell as a host cell.
- a prokaryotic cell when used as a host cell, it generally includes a strong promoter capable of promoting transcription (for example, tac promoter, lac promoter, lacUV5 promoter, lpp promoter, pL promoter, pR promoter, rac5 promoter, amp promoter, recA promoter, SP6 promoter, trp promoter, and T7 promoter), a ribosome binding site for initiation of translation, and a transcription/translation termination sequence.
- a strong promoter capable of promoting transcription for example, tac promoter, lac promoter, lacUV5 promoter, lpp promoter, pL promoter, pR promoter, rac5 promoter, amp promoter, recA promoter, SP6 promoter, trp promoter
- E. coli for example, HB101, BL21, DH5 ⁇ , etc
- the promoter and operator region of E. coli tryptophan biosynthesis pathway (Yanofsky, C., J. Bacteriol., 158:1018-1024(1984)) and the pL promoter of phage (pL promoter, Herskowitz, I. and Hagen, D., Ann. Rev. Genet., 14:399-445(1980)
- pL promoter Herskowitz, I. and Hagen, D., Ann. Rev. Genet., 14:399-445(1980)
- a promoter of a toxin protein gene of Bacillus thuringiensis (Appl. Environ. Microbiol. 64:3932-3938(1998); Mol. Gen. Genet. 250:734-741(1996)) or any promoter capable of expressing in Bacillus can be used as a regulatory region.
- the vector usable in this invention can be constructed by manipulating plasmids (for example, pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8/9, pUC6, pBD9, pHC79, pIJ61, pLAFR1, pHV14, pGEX series, pET series, pRSET, pBluescript, pGEX2T, pCR1, pMB9, RP4, and pUC19 etc.), phages (for example, gt4. B, -Charon, Ez1, and M13) or viruses (for example, SV40 etc.) frequently used in this field.
- plasmids for example, pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8/9, pUC6, pBD9, pHC79, pIJ61
- a promoter originated from a mammalian cell genome for example, metallothionine promoter, ⁇ -actin promoter, human hemoglobin promoter, and human muscle creatine promoter
- a promoter originated from a mammalian virus for example, bovine papulardermatitis virus promoter, adeno-associated virus promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus promoter, HSV tk promoter, mouse mammary tumor virus (MMTV) promoter, HIV LTR promoter, moloney virus promoter, Epstein-Barr virus (EBV) promoter, tobacco mosaic virus promoter, and roas sarcoma virus (RSV) promoter
- a polyadenylation sequence is generally included therein as a transcription termination sequence.
- the vectors of the present invention can be fused with other sequences to facilitate the purification of the antibodies expressed therefrom.
- sequences adequate for the fusion are exemplified by glutathione S-transferase, maltose binding protein, FLAG, and 6 ⁇ His, etc.
- the protein expressed by the vector of the present invention is an antibody
- the expressed antibody can be easily purified through a protein A column without any additional sequence for the purification.
- the vector above can also include a selection marker.
- the selection marker herein is a marker for the selection of a transformed microorganism or a recombinant vector, which can be used to give selectable phenotypes such as drug resistance, nutritional requirements, resistance to cytotoxic agents, or surface protein expression. When a vector containing the selection marker is used, only those cells expressing the selection marker can survive in the selective medium, so that the transformed cells can be easily selected. Any selection marker that can be used in the conventional art can be used. For example, ampicillin, gentamycin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin or tetracycline can be used as a selection marker herein.
- the host cells can be prokaryotic cells such as Escherichia sp., Bacillus sp., Streptomyces sp., Pseudomonas sp., Proteus sp., or Staphylococcus sp., fungi such as Aspergillus sp., yeasts such as Pichia sp., Saccharomyces sp., Schizosaccharomyces sp., or Neurospora sp., other lower eukaryotic cells, or eukaryotic sells such as animal cells and plant cells.
- prokaryotic cells such as Escherichia sp., Bacillus sp., Streptomyces sp., Pseudomonas sp., Proteus sp., or Staphylococcus sp.
- fungi such as Aspergillus sp.
- yeasts such as Pichia
- the conventional gene manipulation method can be used.
- a physical method microinjection, liposome dependent method, direct DNA uptake, receptor-mediated DNA transfer, Ca ++ -directed DNA transfer, or virus-mediated gene transfer can be used.
- the present inventors prepared monoclonal antibodies binding specifically to the spike protein of MERS-CoV.
- 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies were confirmed to have excellent adhesion to the full-length spike protein and S1 antigen of MERS-CoV (see FIGS. 1 and 2 ).
- 90-F1, 90-E5, 90-E6, 90-F2, 77-A5, and 77-A6 antibodies were confirmed to have excellent adhesion to the RBD antigen of MERS-CoV (see FIG. 3 ).
- the present invention also provides a composition for the prevention, treatment or diagnosis of Middle East respiratory syndrome comprising the heavy chain variable region of the monoclonal antibody of the invention.
- the heavy chain variable region above can be characterized by the description above.
- the heavy chain variable region can be the heavy chain variable region of the monoclonal antibody binding specifically to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21.
- CDR complementarity determining region
- composition for the treatment of MERS of the present invention can be administered as an independent drug or can be co-administered with other drugs. In the case of co-treatment, it can be administered simultaneously together with the conventional drug or stepwise.
- composition comprising the heavy chain variable region of the monoclonal antibody above can be used for the treatment of virus infection by introducing into a living body in the form of the antibody-drug conjugate.
- the drug can be a chemotherapeutic agent, a radionuclide, an immunotherapeutic agent, a cytokine, a chemokine, a toxin, a biological agent, or an enzyme inhibitor.
- An example of the method to bind an antibiotic to an antibody is explained in the following references: G. Gregoriadies, ed., Academic Press London, (1979); Arnon et al., Recent Results in Cancer Res., 75: 236 (1980); and Moolton et al., Immunolog. Res., 62:47 (1982).
- the drug that is preferred for the coupling with the antibody of the present invention include antibiotics, antiparasitic, antifungal, and related agents such as, for example, sulfonamide, penicillin and cephalosporin, aminoglycoside, tetracycline, chloramphenicol, piperazine, chloroquine, diaminopyridine, metroniazide, isoniazid, rifampin, streptomycin, sulfone, erythromycin, polymyxin, nistatin, amphotericin, 5-fluorocytosine, 5-iodo-2′-deoxyuridine, 1-adamanthamine, adenine arabinoside, ammanidin, ribavirin or azatrimidine (AZT).
- antibiotics antibiotics, antiparasitic, antifungal, and related agents such as, for example, sulfonamide, penicillin and cephalosporin, aminoglycoside, tetracycline, chlor
- the immunoregulator usable as a drug in the form of the antibody-drug conjugate can be a lymphokine or a cytokine, but not always limited thereto.
- composition for the prevention or treatment of MERS of the present invention can include the heavy chain variable region of the monoclonal antibody of the invention as an active ingredient at the concentration of 10-95 weight % by the total weight of the composition.
- the composition of the present invention can include, in addition to the active ingredient, one or more effective ingredients having the same or similar function to the active ingredient.
- the composition for the prevention or treatment of MERS of the present invention can include any generally used carrier, diluent, excipient, or a combination of at least two of those.
- the pharmaceutically acceptable carrier can be any carrier that is able to deliver the composition of the present invention in a living body without limitation, which is exemplified by the compounds described in Merck Index, 13 th ed., Merck & Co. Inc., such as saline, sterilized water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, liposome and a mixture comprising one or more of those components.
- a general additive such as antioxidant, buffer, and bacteriostatic agent can be additionally added.
- composition of the present invention can be prepared for oral or parenteral administration by mixing with generally used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactant.
- Solid formulations for oral administration are tablets, pills, powders, granules, capsules, and troches. These solid formulations are prepared by mixing the composition of the present invention with one or more suitable excipients such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. Lubricants such as magnesium stearate and talc can also be included therein.
- Liquid formulations for oral administrations are suspensions, solutions, emulsions and syrups, and the above-mentioned formulations can contain various excipients such as wetting agents, sweeteners, aromatics and preservatives.
- Formulations for parenteral administration are sterilized aqueous solutions, water-insoluble excipients, suspensions, and emulsions.
- Water insoluble excipients and suspensions can contain propylene glycol, polyethylene glycol, vegetable oil like olive oil, injectable ester like ethylolate, etc.
- composition for the prevention or treatment of MERS of the present invention can be administered orally or parenterally and the parenteral administration includes intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, intramuscular injection, and intra-thoracic injection.
- composition for the prevention or treatment of MERS of the present invention is administered in a pharmaceutically effective dose.
- the effective dose can be determined by considering many factors such as the type of disease, severity of the disease, activity of the drug, sensitivity to the drug, administration frequency and pathway, excretion, term of treatment, co-treatment drug and other factors regarded as relevant in the medicinal field.
- the composition of the invention can be administered simultaneously together with the other drugs or stepwise.
- the amount of the active ingredient included in the composition of the present invention can be 0.001 ⁇ 10,000 mg/kg, specifically 0.1 ⁇ 5 g/kg.
- the administration frequency can be once a day or a few times a day.
- the diagnostic composition of the present invention indicates a major tool used for the diagnosis of a target disease, which can include the materials useful for diagnosing MERS-CoV according to the purpose of the invention.
- the diagnostic method can include the step of contacting an antibody or an antibody fragment with a sample.
- the sample herein can be sputum, cells or a tissues taken from nasal cavity, sinus cavity, salivary gland, lung, liver, pancreas, kidney, ear, eye, placenta, digestive tract, heart, ovary, pituitary, adrenal, thyroid, brain or skin, urine, whole blood, serum, plasma, feces, cell culture supernatant, or ruptured eukaryotic cells.
- sample-antibody conjugate can be detected by colormetric method, electrochemical method, fluorimetric method, luminometry, particle counting method, visual assessment, or scintillation counting method.
- the detection is to detect the sample-antibody conjugate, for which various markers can be used.
- a marker an enzyme, a fluorescent material, a ligand, a luminescent material, a microparticle or a radioactive isotope can be used.
- the enzyme usable as a detection marker is exemplified by acetylcholinesterase, alkaline phosphatase, ⁇ -D-galactosidase, horseradish peroxidase, and ⁇ -lactamase.
- the fluorescent material usable as a detection marker can be fluorescein, Eu 3+ , Eu 3+ chelate, or cryptate.
- a biotin derivative can be used.
- As the luminescent material acridinium ester and an isoluminol derivative can be used.
- Colloidal gold and colored latex can be used as the microparticle, and 57 Co, 3 H, 125 I, and 125 I-Bonton Hunter reagent can be used as the radioactive isotope.
- the present inventors prepared monoclonal antibodies binding specifically to the spike protein of MERS-CoV.
- 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies were confirmed to have excellent adhesion to the full-length spike protein and S1 antigen of MERS-CoV (see FIGS. 1 and 2 ).
- 90-F1, 90-E5, 90-E6, 90-F2, 77-A5, and 77-A6 antibodies were confirmed to have excellent adhesion to the RBD antigen of MERS-CoV (see FIG. 3 ).
- 77-A5, 77-A6, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies exhibited neutralizing ability against MERS pseudovirus and MERS-CoV
- 90-B2 and 90-B7 antibodies showed neutralizing ability only against MERS-CoV (see FIGS. 5 a , FIG. 5 b , FIG. 6 a and FIG. 6 b ).
- the monoclonal antibodies above were confirmed to be in the form of a certain monomer (see FIG. 7 ) and have excellent stability (see FIG. 9 a to 9c).
- the present invention also provides a kit for the detection or quantification of an antigen of Middle East respiratory syndrome by using the antibody and protein comprising the heavy chain variable region of the monoclonal antibody of the invention.
- the heavy chain variable region above can be characterized by the description above.
- the heavy chain variable region can be the heavy chain variable region of the monoclonal antibody binding specifically to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21.
- CDR complementarity determining region
- the said kit can be prepared by the conventional method well known to those in the art.
- the kit can additionally include a buffer, a stabilizer, and an inactive protein.
- the kit can be used in the following method: fluorescence method performed by detecting fluorescence of the fluorescent material attached as a detection marker to investigate the amount of the detection reagent, high throughput screening (HTS) system through radiation method performed by detecting radiation of the radioactive isotope attached as a detection marker, surface plasmon resonance (SPR) method to measure the surface plasmon resonance change in real time without labeling a detection marker, or surface plasmon resonance imaging (SPRI) method for imaging and verifying SPR system.
- fluorescence method performed by detecting fluorescence of the fluorescent material attached as a detection marker to investigate the amount of the detection reagent
- high throughput screening (HTS) system through radiation method performed by detecting radiation of the radioactive isotope attached as a detection marker
- SPR surface plasmon resonance
- SPRI surface plasmon resonance imaging
- the present inventors prepared monoclonal antibodies binding specifically to the spike protein of MERS-CoV.
- 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies were confirmed to have excellent adhesion to the full-length spike protein and S1 antigen of MERS-CoV (see FIGS. 1 and 2 ).
- 90-F1, 90-E5, 90-E6, 90-F2, 77-A5, and 77-A6 antibodies were confirmed to have excellent adhesion to the RBD antigen of MERS-CoV (see FIG. 3 ).
- 77-A5, 77-A6, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies exhibited neutralizing ability against MERS pseudovirus and MERS-CoV
- 90-B2 and 90-B7 antibodies showed neutralizing ability only against MERS-CoV (see FIGS. 5 a , FIG. 5 b , FIG. 6 a and FIG. 6 b ).
- the monoclonal antibodies above were confirmed to be in the form of a certain monomer (see FIG. 7 ) and have excellent stability (see FIG. 9 a to FIG. 9 c ).
- the present invention also provides a method for preventing, treating or diagnosing Middle East respiratory syndrome comprising a step of administering the heavy chain variable region of the monoclonal antibody of the invention to a subject.
- the heavy chain variable region above can be characterized by the description above.
- the heavy chain variable region can be the heavy chain variable region of the monoclonal antibody binding specifically to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21.
- CDR complementarity determining region
- the subject can be a mammal, specifically a human.
- the heavy chain variable region of the present invention can be administered orally or parenterally and the parenteral administration includes intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, intramuscular injection, and intra-thoracic injection.
- the heavy chain variable region of the present invention is administered in a pharmaceutically effective dose.
- the effective dose can be determined by considering many factors such as the type of disease, severity of the disease, activity of the drug, sensitivity to the drug, administration frequency and pathway, excretion, term of treatment, co-treatment drug and other factors regarded as relevant in the medicinal field.
- the heavy chain variable region of the invention can be administered simultaneously together with the other drugs or stepwise.
- the amount of the active ingredient included in the heavy chain variable region of the present invention can be 0.001-10,000 mg/kg, specifically 0.1-5 g/kg.
- the administration frequency can be once a day or a few times a day.
- the heavy chain variable region of the present invention indicates a major tool used for the diagnosis of a target disease, which can include the materials useful for diagnosing MERS-CoV according to the purpose of the invention.
- the diagnostic method can include the step of contacting an antibody or an antibody fragment with a sample.
- the sample herein can be sputum, cells or a tissues taken from nasal cavity, sinus cavity, salivary gland, lung, liver, pancreas, kidney, ear, eye, placenta, digestive tract, heart, ovary, pituitary, adrenal, thyroid, brain or skin, urine, whole blood, serum, plasma, feces, cell culture supernatant, or ruptured eukaryotic cells.
- sample-antibody conjugate can be detected by colormetric method, electrochemical method, fluorimetric method, luminometry, particle counting method, visual assessment, or scintillation counting method.
- the detection is to detect the sample-antibody conjugate, for which various markers can be used.
- a marker an enzyme, a fluorescent material, a ligand, a luminescent material, a microparticle or a radioactive isotope can be used.
- the enzyme usable as a detection marker is exemplified by acetylcholinesterase, alkaline phosphatase, ⁇ -D-galactosidase, horseradish peroxidase, and ⁇ -lactamase.
- the fluorescent material usable as a detection marker can be fluorescein, Eu3+, Eu3+ chelate, or cryptate.
- a biotin derivative can be used.
- As the luminescent material acridinium ester and an isoluminol derivative can be used.
- Colloidal gold and colored latex can be used as the microparticle, and 57Co, 3H, 125I, and 125I-Bonton Hunter reagent can be used as the radioactive isotope.
- the present invention also provides a use of the heavy chain variable region of the monoclonal antibody of the invention for the manufacture of a medicament for preventing, treating or diagnosing Middle East respiratory syndrome.
- the heavy chain variable region above can be characterized by the description above.
- the present invention also provides a light chain variable region of the monoclonal antibody specifically binding to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- CDR complementarity determining region
- the spike protein above can be characterized by the description above.
- the spike protein can be composed of the amino acid sequence represented by SEQ. ID. NO: 23.
- the said light chain variable region can specifically bind to the 1 st to 757 th amino acid sites from the N-terminus of the spike protein of MERS-CoV.
- the light chain variable region of the monoclonal antibody whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 16, 18, 20, or NO: 22 can bind specifically to the 377 th to 588 th amino acid sites from the N-terminus of the spike protein of MERS-CoV.
- the present invention also provides a gene encoding the light chain variable region of the monoclonal antibody of the invention; a recombinant vector containing the gene above; and a host cell introduced with the gene or the recombinant vector above.
- the light chain variable region above can be characterized by the description above.
- the light chain variable region can be the light chain variable region of the monoclonal antibody binding specifically to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- CDR complementarity determining region
- the said vector is a recombinant vector capable of expressing a target peptide in a desired host cell, which indicates a gene construct containing a necessary regulatory element operably linked thereto in order to express the gene insert.
- Various host cells can be used in order to express the light chain variable region of the monoclonal antibody according to the present invention.
- the usable host cells are characterized by the description above.
- the conventional gene manipulation method can be used.
- a physical method microinjection, liposome dependent method, direct DNA uptake, receptor-mediated DNA transfer, Ca ++ -directed DNA transfer, or virus-mediated gene transfer can be used.
- the present invention also provides a composition for the prevention, treatment or diagnosis of Middle East respiratory syndrome comprising the light chain variable region of the monoclonal antibody of the invention.
- the light chain variable region above can be characterized by the description above.
- the light chain variable region can be the light chain variable region of the monoclonal antibody binding specifically to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- CDR complementarity determining region
- composition for the prevention or treatment of the invention is characterized by the description above.
- the diagnostic composition of the present invention indicates a major tool used for the diagnosis of a target disease, which can include the materials useful for diagnosing MERS-CoV according to the purpose of the invention.
- the diagnostic method can include the step of contacting an antibody or an antibody fragment with a sample.
- the sample herein can be sputum, cells or a tissues taken from nasal cavity, sinus cavity, salivary gland, lung, liver, pancreas, kidney, ear, eye, placenta, digestive tract, heart, ovary, pituitary, adrenal, thyroid, brain or skin, urine, whole blood, serum, plasma, feces, cell culture supernatant, or ruptured eukaryotic cells.
- the present invention also provides a kit for the detection or quantification of an antigen of Middle East respiratory syndrome by using the antibody and protein comprising the light chain variable region of the monoclonal antibody of the invention.
- the light chain variable region above can be characterized by the description above.
- the light chain variable region can be the light chain variable region of the monoclonal antibody binding specifically to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- CDR complementarity determining region
- the kit above is characterized by the description above.
- it can be prepared by the conventional method known to those in the art, and can additionally include a buffer, a stabilizer, and an inactive protein, etc.
- the kit can be used in the following method: fluorescence method performed by detecting fluorescence of the fluorescent material attached as a detection marker to investigate the amount of the detection reagent, high throughput screening (HTS) system through radiation method performed by detecting radiation of the radioactive isotope attached as a detection marker, surface plasmon resonance (SPR) method to measure the surface plasmon resonance change in real time without labeling a detection marker, or surface plasmon resonance imaging (SPRI) method for imaging and verifying SPR system.
- fluorescence method performed by detecting fluorescence of the fluorescent material attached as a detection marker to investigate the amount of the detection reagent
- high throughput screening (HTS) system through radiation method performed by detecting radiation of the radioactive isotope attached as a detection marker
- SPR surface plasmon resonance
- the present invention also provides a method for preventing, treating or diagnosing Middle East respiratory syndrome comprising a step of administering the light chain variable region of the monoclonal antibody of the invention to a subject.
- the light chain variable region above can be characterized by the description above.
- the light chain variable region can be the light chain variable region of the monoclonal antibody binding specifically to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- CDR complementarity determining region
- the subject can be a mammal, specifically a human.
- the light chain variable region of the present invention can be administered orally or parenterally and the parenteral administration includes intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, intramuscular injection, and intra-thoracic injection.
- the light chain variable region of the present invention is administered in a pharmaceutically effective dose.
- the effective dose can be determined by considering many factors such as the type of disease, severity of the disease, activity of the drug, sensitivity to the drug, administration frequency and pathway, excretion, term of treatment, co-treatment drug and other factors regarded as relevant in the medicinal field.
- the light chain variable region of the invention can be administered simultaneously together with the other drugs or stepwise.
- the amount of the active ingredient included in the light chain variable region of the present invention can be 0.001-10,000 mg/kg, specifically 0.1-5 g/kg.
- the administration frequency can be once a day or a few times a day.
- the light chain variable region of the present invention indicates a major tool used for the diagnosis of a target disease, which can include the materials useful for diagnosing MERS-CoV according to the purpose of the invention.
- the diagnostic method can include the step of contacting an antibody or an antibody fragment with a sample.
- the sample herein can be sputum, cells or a tissues taken from nasal cavity, sinus cavity, salivary gland, lung, liver, pancreas, kidney, ear, eye, placenta, digestive tract, heart, ovary, pituitary, adrenal, thyroid, brain or skin, urine, whole blood, serum, plasma, feces, cell culture supernatant, or ruptured eukaryotic cells.
- sample-antibody conjugate can be detected by colormetric method, electrochemical method, fluorimetric method, luminometry, particle counting method, visual assessment, or scintillation counting method.
- the detection is to detect the sample-antibody conjugate, for which various markers can be used.
- a marker an enzyme, a fluorescent material, a ligand, a luminescent material, a microparticle or a radioactive isotope can be used.
- the enzyme usable as a detection marker is exemplified by acetylcholinesterase, alkaline phosphatase, ⁇ -D-galactosidase, horseradish peroxidase, and ⁇ -lactamase.
- the fluorescent material usable as a detection marker can be fluorescein, Eu3+, Eu3+ chelate, or cryptate.
- a biotin derivative can be used.
- As the luminescent material acridinium ester and an isoluminol derivative can be used.
- Colloidal gold and colored latex can be used as the microparticle, and 57Co, 3H, 125I, and 125I-Bonton Hunter reagent can be used as the radioactive isotope.
- the present invention also provides a use of the light chain variable region of the monoclonal antibody of the invention for the manufacture of a medicament for preventing, treating or diagnosing Middle East respiratory syndrome.
- the light chain variable region above can be characterized by the description above.
- the present invention also provides a monoclonal antibody specifically binding to the spike protein of MERS-CoV containing a heavy chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21, and a light chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- the spike protein above can be characterized by the description above.
- the spike protein can be composed of the amino acid sequence represented by SEQ. ID. NO: 23.
- the light chain variable region and the heavy chain variable region can be characterized by the description above.
- the monoclonal antibody is an antibody produced by a single antibody-forming cell, which has a uniform primary structure (amino acid sequence).
- the monoclonal antibody recognizes only one antigenic determinant and is generally produced by culturing the hybridoma cells prepared by the fusion of cancer cells and antibody producing cells. This antibody also can be produced by using other recombinant protein expressing host cells using the obtained antibody gene sequence.
- the present invention also provides a gene encoding the monoclonal antibody of the invention; a recombinant vector containing the gene above; and a host cell introduced with the gene or the recombinant vector above.
- the monoclonal antibody above can be characterized by the description above.
- the monoclonal antibody can be the antibody binding specifically to the spike protein of MERS-CoV containing a heavy chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21, and a light chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- the said vector is a recombinant vector capable of expressing a target peptide in a desired host cell, which indicates a gene construct containing a necessary regulatory element operably linked thereto in order to express the gene insert.
- Various host cells can be used in order to express the monoclonal antibody according to the present invention.
- the usable host cells are characterized by the description above.
- the conventional gene manipulation method can be used.
- a physical method microinjection, liposome dependent method, direct DNA uptake, receptor-mediated DNA transfer, Ca ++ -directed DNA transfer, or virus-mediated gene transfer can be used.
- the present invention also provides a composition for the prevention, treatment or diagnosis of Middle East respiratory syndrome comprising the monoclonal antibody of the invention.
- the monoclonal antibody above can be characterized by the description above.
- the monoclonal antibody can be the antibody binding specifically to the spike protein of MERS-CoV containing a heavy chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21, and a light chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- composition for the prevention or treatment of the invention is characterized by the description above.
- the diagnostic composition of the present invention indicates a major tool used for the diagnosis of a target disease, which can include the materials useful for diagnosing MERS-CoV according to the purpose of the invention.
- the diagnostic method can include the step of contacting an antibody or an antibody fragment with a sample.
- the sample herein can be sputum, cells or a tissues taken from nasal cavity, sinus cavity, salivary gland, lung, liver, pancreas, kidney, ear, eye, placenta, digestive tract, heart, ovary, pituitary, adrenal, thyroid, brain or skin, urine, whole blood, serum, plasma, feces, cell culture supernatant, or ruptured eukaryotic cells.
- the present invention also provides a kit for the detection or quantification of an antigen of Middle East respiratory syndrome comprising the monoclonal antibody of the invention.
- the monoclonal antibody above can be characterized by the description above.
- the monoclonal antibody can be the antibody binding specifically to the spike protein of MERS-CoV containing a heavy chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21, and a light chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- the kit above is characterized by the description above.
- it can be prepared by the conventional method known to those in the art, and can additionally include a buffer, a stabilizer, and an inactive protein, etc.
- the kit can be used in the following method: fluorescence method performed by detecting fluorescence of the fluorescent material attached as a detection marker to investigate the amount of the detection reagent, high throughput screening (HTS) system through radiation method performed by detecting radiation of the radioactive isotope attached as a detection marker, surface plasmon resonance (SPR) method to measure the surface plasmon resonance change in real time without labeling a detection marker, or surface plasmon resonance imaging (SPRI) method for imaging and verifying SPR system.
- fluorescence method performed by detecting fluorescence of the fluorescent material attached as a detection marker to investigate the amount of the detection reagent
- high throughput screening (HTS) system through radiation method performed by detecting radiation of the radioactive isotope attached as a detection marker
- SPR surface plasmon resonance
- the present invention also provides a method for preventing, treating or diagnosing Middle East respiratory syndrome comprising a step of administering the monoclonal antibody of the invention to a subject.
- the monoclonal antibody above can be characterized by the description above.
- the monoclonal antibody can be the antibody binding specifically to the spike protein of MERS-CoV containing a heavy chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21, and a light chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- the subject can be a mammal, specifically a human.
- the monoclonal antibody of the present invention can be administered orally or parenterally and the parenteral administration includes intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, intramuscular injection, and intra-thoracic injection.
- the monoclonal antibody of the present invention is administered in a pharmaceutically effective dose.
- the effective dose can be determined by considering many factors such as the type of disease, severity of the disease, activity of the drug, sensitivity to the drug, administration frequency and pathway, excretion, term of treatment, co-treatment drug and other factors regarded as relevant in the medicinal field.
- co-treatment The monoclonal antibody of the invention can be administered simultaneously together with the other drugs or stepwise.
- the amount of the active ingredient included in the monoclonal antibody of the present invention can be 0.001 ⁇ 10,000 mg/kg, specifically 0.1 ⁇ 5 g/kg.
- the administration frequency can be once a day or a few times a day.
- the monoclonal antibody of the present invention indicates a major tool used for the diagnosis of a target disease, which can include the materials useful for diagnosing MERS-CoV according to the purpose of the invention.
- the diagnostic method can include the step of contacting an antibody or an antibody fragment with a sample.
- the sample herein can be sputum, cells or a tissues taken from nasal cavity, sinus cavity, salivary gland, lung, liver, pancreas, kidney, ear, eye, placenta, digestive tract, heart, ovary, pituitary, adrenal, thyroid, brain or skin, urine, whole blood, serum, plasma, feces, cell culture supernatant, or ruptured eukaryotic cells.
- sample-antibody conjugate can be detected by colormetric method, electrochemical method, fluorimetric method, luminometry, particle counting method, visual assessment, or scintillation counting method.
- the detection is to detect the sample-antibody conjugate, for which various markers can be used.
- a marker an enzyme, a fluorescent material, a ligand, a luminescent material, a microparticle or a radioactive isotope can be used.
- the enzyme usable as a detection marker is exemplified by acetylcholinesterase, alkaline phosphatase, ⁇ -D-galactosidase, horseradish peroxidase, and ⁇ -lactamase.
- the fluorescent material usable as a detection marker can be fluorescein, Eu3+, Eu3+ chelate, or cryptate.
- a biotin derivative can be used.
- As the luminescent material acridinium ester and an isoluminol derivative can be used.
- Colloidal gold and colored latex can be used as the microparticle, and 57Co, 3H, 125I, and 125I-Bonton Hunter reagent can be used as the radioactive isotope.
- the present invention also provides a use of the monoclonal antibody of the invention for the manufacture of a medicament for preventing, treating or diagnosing Middle East respiratory syndrome.
- the monoclonal antibody above can be characterized by the description above.
- PBMCs Peripheral blood mononuclear cells
- B cells having MERS antibody were separated as single cells (single cell sorting) from the PBMCs isolated by FACS using the MERS-CoV spike trimer protein probe (PE fluorescent dye), anti-human IgG-FITC and anti-human CD20 IgG-Cy55PerCP, provided by NIH/NIAID/VRC, USA.
- Unnecessary immune cells except B cells were negatively selected by attaching CD3, CD4, CD8 and CD14 markers and removed by FACS.
- CDR regions of the heavy chain, kappa light chain and lambda light chain of the antibody gene separated from the B cells obtained from patients with early phase MERS were amplified by PCR, and the sequences were confirmed.
- the nucleotide sequence appropriate for the immunoglobulin antibody expression was examined by using a web-based IMGT (International Immunogenetics Information systems, http://www.imgt.org) program.
- CDR regions of the heavy chain, kappa light chain and lambda light chain of the antibody were cloned in pVRC vector comprising mouse IgM signal peptide and IgG constant region provided by NIH/NIAID/VRC, USA.
- Expi293F cells were transfected with the prepared antibody plasmid. 5 days later, the cell culture fluid was obtained, from which the antibody was prepared by purifying with protein G agarose column.
- the adhesion was compared among the monoclonal antibodies prepared in Example 1, the human anti-S1 monoclonal antibodies A2 and A10, the human anti-RBD monoclonal antibody C2, the mouse anti-S2 monoclonal antibody G4, and the mouse anti-S1 monoclonal antibody G2, developed by NIH, USA.
- MERS-CoV full spike trimer antigen was loaded in MaxiSorp 96-well plate (Nunc) at the concentration of 0.2 ⁇ g/100 ⁇ PBS/well, followed by reaction at 4° C. for a day. Upon completion of the reaction, the reaction solution was eliminated, followed by blocking with a blocking solution containing 5% skim milk and 2% BSA in PBST at room temperature for 1 hour. Next, the antibody prepared in Example 1 was diluted in the blocking solution at the concentration of 10, 2.5, 0.625, 0.15625, 0.039, 0.009, 0.002, 0.0006, or 0.0001 ⁇ g/m , which was loaded in the plate coated with the full spike trimer antigen above, followed by reaction at room temperature for 1 hour.
- the plate was washed with PBST 6 times, to which rabbit anti-human IgG H&L-HRP (horse radish peroxidase) secondary antibody was added, followed by reaction for 1 hour.
- Anti-mouse IgG-HRP secondary antibody was added to the well containing G2 and G4 antibodies, followed by reaction for 1 hour.
- 100 ⁇ of TMB solution was added to each well, followed by reaction at room temperature for 30 minutes with blocking light.
- 100 ⁇ of stop solution Enzygost was added to each well.
- OD 450 was measured to investigate the antibody adhesion to antigen.
- the binding affinity of 24 kinds of the antibodies prepared in Example 1 was investigated by the same manner as described in Experimental Example 1-1 except that the MERS-CoV S1 domain composed of amino acids 1 to 757 from the N-terminus of the spike protein was used as an antigen.
- the binding affinity of 24 kinds of the antibodies prepared in Example 1 was investigated by the same manner as described in Experimental Example 1-1 except that the MERS-CoV RBD (receptor binding domain) composed of amino acids 377 to 588 from the N-terminus of the spike protein was used as an antigen.
- MERS-CoV RBD receptor binding domain
- the binding affinity of 24 kinds of the antibodies prepared in Example 1 was investigated by the same manner as described in Experimental Example 1-1 except that the MERS-CoV S2 domain composed of amino acids 757 to 1275 from the N-terminus of the spike protein was used as an antigen.
- Huh7.5 cell line was treated with trypsin and suspended.
- the cells were diluted with DMEM (Dulbecco's modified Eagle's medium) containing 10% FBS, which were distributed in a 96-well tissue culture late at the density of 10 4 cells/100 ⁇ /well, followed by culture for a day.
- DMEM Dulbecco's modified Eagle's medium
- the mixture was added to the culture plate (50 ⁇ /well), to which DMEM containing 10% FBS was added (100 ⁇ /well), followed by culture in a 37° C., 5% CO 2 incubator for 3 days. After discarding the culture fluid, 1 ⁇ lysis buffer (Promega, E153A) was added therein at the concentration of 25 ⁇ /well, followed by stirring for 15 minutes to lyse the cells. The lysed cells were added with luciferase substrate reagent (Promega, E151A) (50 ⁇ /well). Fluorescence was measured with a luminometer and neutralizing capacity was calculated by the following mathematical formula 1.
- 77-A5, 77-A6, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies demonstrated neutralizing capacity against MERS pseudovirus Erasmus strain.
- 77-A5, 77-A6, 90-F1, and 90-F2 antibodies showed neutralizing capacity against MERS pseudovirus Bisha 1 strain as well.
- 90-F1 antibody displayed the highest neutralizing capacity against MERS pseudovirus Erasmus strain and Bisha 1 strain ( FIG. 5 a , FIG. 5 b and Table 2). Therefore, it was confirmed that 77-A5, 77-A6, 90-F1, and 90-F2 antibodies had a wide range of neutralizing capacity.
- plaque reduction neutralizing test was performed with MERS-CoV (Erasmus strain and KNIH strain).
- MERS-CoV Erasmus strain and KNIH strain.
- Vero cells were distributed in a 24-well plate at the density of 10 5 cells/well, followed by culture. The culture medium was discarded therefrom.
- the antibodies of Example 1 diluted in cell culture medium at the concentration of 10, 2.5, 0.625, 0.156, 0.039, 0.009, or 0.002 ng/m were mixed with the MERS-CoV (EMC, KNIH-002, KNIH-016, and KNIH-042 strains) diluted in 50 PFU/well, resulting in the preparation of a mixed solution.
- EMC EMC, KNIH-002, KNIH-016, and KNIH-042 strains
- the mixed solution was added to the culture plate at the concentration of 100 ⁇ /well, followed by reaction at 37° C. for 1 hour. Then, DMEM containing 1.5% CMC (carboxymethyl cellulose) was added to the plate at the concentration of 1 m /well, followed by culture for 3 days. Upon completion of the culture, plaques were observed by crystal violet staining. The number of plaques in each well was calculated, based on which neutralizing capacity was calculated by the following mathematical formula 2. ND 50 was also calculated by the following mathematical formula 3 to calculate the neutralizing capacity.
- m indicates a log 10 value of the highest rate of dilution
- ⁇ indicates a constant interval between the rates of dilution expressed by a log 10 value
- ⁇ p indicates the average number of plaques for sum of all ratios of plaques/virus control.
- Neutralizing Capacity (%) 100 ⁇ (plaque number of antibody-treated MERS virus/plaque number of antibody-non-treated MERS virus ⁇ 100) [Mathematical Formula 2]
- the antibody morphology was analyzed by using water SEC-HPLC system.
- Agilent Bio SEC3 was used as the HPLC column and ultraviolet absorption spectrophotometer (280 nm) was used as the detector.
- 10 ⁇ of each antibody was loaded as the sample at the concentration of 1 mg/m .
- the flow rate was 0.3 m /min.
- 1 ⁇ PBS was used as a moving phase for isocratic elution.
- the avidity of the antibodies was analyzed by SPR assay using S1 antigen or RBD antigen. Particularly, S1 antigen or RBD antigen was attached on the surface of CM5 chip, to which the antibody was loaded. The association time was 3 minutes and the dissociation time was as listed in Table 4. HBS-EP was used as a running buffer, and regeneration solution was as shown in Table 4 for SPR assay.
- the antibodies 77-A5 and 90-B2 attached with S1 antigen showed a high avidity to the S1 antigen, confirmed by the low Kr, value of up to 75 pM.
- the antibody 90-F1 attached with RBD antigen showed a high avidity to the RBD antigen, confirmed by the low K D value of up to 72 pM.
- 90-B2 and 90-B7 antibodies did not bind to the RBD antigen, indicating that the 90-B2 and 90-B7 antibodies were specific to the S1 antigen ( FIG. 8 a , FIG. 8 b and Table 5).
- the antibody stability was investigated in PBS (phosphate buffered saline, pH 7.4) which included neither calcium nor magnesium. Particularly, 0.75 ⁇ g of each antibody prepared in Example 1 was used. PTS assay was performed by using Protein Thermal ShiftTM Dye Kit (Catalog No. 4466038, Life technologies) according to the manufacturer's protocol.
- the melting points of 77-A5, 77-A6, 90-B2, 90-B7, 90-F1, and 90-F2 antibodies were respectively 67.52° C., 68.44° C. and 75.44° C., 72.46° C., 68.21° C. and 81.19° C., 69.21° C. and 79.81° C., and 68.89° C. and 75.10° C. Therefore, all of the six antibodies were confirmed to have a stable structure because the protein hydrophobicity was exposed at the temperature of 67.52° C. or higher ( FIG. 9 a to FIG. 9 c ).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
- The present invention relates to monoclonal antibodies for a spike protein of Middle East respiratory syndrome coronavirus and a use thereof.
- Middle East respiratory syndrome (MERS) was first identified in the Middle East region in September 2012. According to the report made by WHO, MERS spread to 26 countries as of Jun. 5, 2017, resulting in 1,980 confirmed patients and 693 deaths worldwide. It is a high-risk disease with a mortality rate of 35%.
- Middle East respiratory syndrome coronavirus (MERS-CoV), the pathogen of MERS, is a newly discovered beta-coronavirus (YCoV), which was first found in 2012. This virus is a 30-kb (+)-sense single-stranded RNA virus, and is similar to severe acute respiratory syndrome (SARS) virus. MERS-CoV penetrates into cells as being conjugated with a human DPP4 (dipeptidyl peptidase 4) receptor by using a spike protein (S protein) (Wang N, Shi X, Jiang L J, Zhang S, Wang D, Tong P, Guo D, et al., Cell Research. 2013:23:986). MERS-CoV has a latency of about one week and causes severe respiratory symptoms such as high fever, coughing, and difficulty in breathing, etc.
- For the treatment of MERS, the immunomodulator interferon and the anti-viral agent ribarvirin or lopinavir are used (Public Health England, ISARIC, 2015. Sep. 5. ver 3.0; Chung Y P, Song J Y, Seo Y B, et al., Infection & Chemotherapy. 2015). Interferon is an immune protein released when a virus or germ enters in a human body, inducing the surrounding cells to emit antiviral cytokines, inhibiting virus proliferation, and inviting immune cells to remove the virus-infected cells. However, the use of interferon can cause side effects such as bone marrow suppression, anemia, decrease of white cell number, or decrease of platelet number.
- Ribarvirin, the antiviral agent, inhibits the proliferation of various types of viruses by interrupting the RNA synthesis thereof in the form of a nucleoside analogue. However, ribarvirin also induces side effects such as toxicity, carcinogenesis, or hemolytic anemia. The administration of interferon and ribarvirin for the treatment of MERS has not been supported by the clinical tests. In the rhesus monkey animal model, the co-administration of interferon and ribarvirin was effective in treating MERS (Falzarano D, Wit E, Rasmussen A L., et al., Nature Medicine, 2013, 19, 10, p 1313-1318). However, when interferon and ribarvirin were co-administered to 5 MERS patients with severe conditions in Middle East, the treatment effect was hardly observed (Al-Tawfiq J A, Momattin H., Dib J., et al., International Journal of Infectious Diseases 2014, 20, p 42-46). Therefore, it is urgently requested to develop a biologically safe therapeutic antibody that can be used for severe MERS patients, immunocompromised patients, and underlying disease patients with suppressing virus proliferation effectively.
- In relation to the above, Korean Patent No 10-1593641 describes a monoclonal antibody binding specifically to MERS-CoV nucleocapsid and a composition for diagnosing MERS-CoV comprising the same.
- Thus, the present inventors tried to develop therapeutic antibodies for MERS-CoV. As a result, the inventors succeeded in preparation of 24 kinds of monoclonal antibodies specifically binding to the spike protein of MERS-CoV. The inventors further confirmed that 11 antibodies (77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1, and 90-F2) among them had excellent adhesion to MERS-CoV full-length spike and S1 antigen, and 90-F1, 90-E5, 90-E6, 90-F2, 77-A5, and 77-A6 antibodies demonstrated excellent adhesion to MERS-CoV RBD antigen. Also, 77-A5, 77-A6, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies showed neutralizing ability against MERS pseudovirus and MERS-CoV, 90-B2 and 90-B7 antibodies showed neutralizing ability only against MERS-CoV. In addition, the present inventors further confirmed that the antibodies of the present invention are in the form of a certain monomer and have excellent physical stability, leading to the completion of the present invention.
- It is an object of the present invention to provide a monoclonal antibody binding specifically to the spike protein of Middle East respiratory syndrome coronavirus.
- It is another object of the present invention to provide a gene encoding the monoclonal antibody of the invention, a recombinant vector comprising thereof, and a host cell introduced with the gene or the recombinant vector above.
- It is also an object of the present invention to provide a use of the prevention, treatment or diagnosis of Middle East respiratory syndrome comprising the monoclonal antibody of the invention.
- It is further an object of the present invention to provide a kit for the detection or quantification of an antigen of Middle East respiratory syndrome comprising the monoclonal antibody of the invention.
- To achieve the above objects, the present invention provides a heavy chain variable region of the monoclonal antibody specifically binding to the MERS-CoV spike protein whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21.
- The present invention also provides a gene encoding the heavy chain variable region of the monoclonal antibody of the invention.
- The present invention also provides a recombinant vector comprising the gene encoding the heavy chain variable region of the monoclonal antibody of the invention.
- The present invention also provides a host cell introduced with the gene encoding the heavy chain variable region of the monoclonal antibody of the invention or the recombinant vector comprising the gene above.
- The present invention also provides a composition for the prevention, treatment or diagnosis of Middle East respiratory syndrome comprising the heavy chain variable region of the monoclonal antibody of the invention.
- The present invention also provides a kit for the detection or quantification of an antigen of Middle East respiratory syndrome comprising the heavy chain variable region of the monoclonal antibody of the invention.
- The present invention also provides a light chain variable region of the monoclonal antibody specifically binding to the MERS-CoV spike protein whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- The present invention also provides a gene encoding the light chain variable region of the monoclonal antibody of the invention.
- The present invention also provides a recombinant vector comprising the gene encoding the light chain variable region of the monoclonal antibody of the invention.
- The present invention also provides a host cell introduced with the gene encoding the light chain variable region of the monoclonal antibody of the invention or the recombinant vector comprising the gene above.
- The present invention also provides a composition for the prevention, treatment or diagnosis of Middle East respiratory syndrome comprising the light chain variable region of the monoclonal antibody of the invention.
- The present invention also provides a kit for the detection or quantification of an antigen of Middle East respiratory syndrome comprising the light chain variable region of the monoclonal antibody of the invention.
- The present invention also provides a monoclonal antibody specifically binding to the MERS-CoV spike protein containing a heavy chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21, and a light chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- The present invention also provides a gene encoding the monoclonal antibody of the invention.
- The present invention also provides a recombinant vector containing the gene encoding the monoclonal antibody of the invention.
- The present invention also provides a host cell introduced with the gene encoding the monoclonal antibody of the invention or the recombinant vector comprising the gene above.
- The present invention also provides a composition for the prevention, treatment or diagnosis of Middle East respiratory syndrome comprising the monoclonal antibody of the invention.
- The present invention provides a kit for the detection or quantification of an antigen of Middle East respiratory syndrome comprising the monoclonal antibody of the invention.
- The present invention also provides a method for preventing, treating or diagnosing Middle East respiratory syndrome comprising a step of administering the heavy chain variable region of the monoclonal antibody of the invention to a subject.
- The present invention also provides a use of the heavy chain variable region of the monoclonal antibody of the invention for the manufacture of a medicament for preventing, treating or diagnosing Middle East respiratory syndrome.
- The present invention also provides a method for preventing, treating or diagnosing Middle East respiratory syndrome comprising a step of administering the light chain variable region of the monoclonal antibody of the invention to a subject.
- The present invention also provides a use of the light chain variable region of the monoclonal antibody of the invention for the manufacture of a medicament for preventing, treating or diagnosing Middle East respiratory syndrome.
- The present invention also provides a method for preventing, treating or diagnosing Middle East respiratory syndrome comprising a step of administering the monoclonal antibody of the invention to a subject.
- In addition, the present invention provides a use of the monoclonal antibody of the invention for the manufacture of a medicament for preventing, treating or diagnosing Middle East respiratory syndrome.
- Monoclonal antibodies 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1 and 90-F2 according to the present invention have excellent attachment force with respect to a full-length spike protein of MERS-CoV and the S1 domain of the protein, and, of the monoclonal antibodies, the monoclonal antibodies 90-F1, 90-E5, 90-E6, 90-F2, 77-A5 and 77-A6 have excellent attachment force with respect to an RBD antigen of MERS-CoV. Also, the antibodies 77-A5, 77-A6, 90-E5, 90-E6, 90-F1 and 90-F2 exhibit neutralizing capacity with respect to a MERS pseudovirus and MERS-CoV, and the antibodies 90-B2 and 90-B7 exhibit neutralizing capacity only with respect to MERS-CoV. Further, the monoclonal antibodies have a particular monomeric form, and have excellent stability and thus may be useful for treating or diagnosing MERS.
- The application of the preferred embodiments of the present invention is best understood with reference to the accompanying drawings, wherein:
-
FIG. 1 is a graph illustrating the adhesion of 77-A1, 77-A4, 77-A5, 77-A6, 77-A9, 77-A10, 77-A11, 77-A12, 77-B3, 77-B4, 77-B12, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-C5, 90-D6, 90-E1, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies to the full-length spike trimer antigen of MERS-CoV. Herein, C2, A2, A10, G2, and G4 antibodies developed by NIH, USA, were used as the positive controls. -
FIG. 2 is a graph illustrating the adhesion of the antibodies above to the MERS-CoV S1 antigen composed of theamino acids 1 to 757 of the spike protein. -
FIG. 3 is a graph illustrating the adhesion of the antibodies above to the MERS-CoV RBD antigen composed of the amino acids 377 to 588 of the spike protein. -
FIG. 4 is a graph illustrating the adhesion of the antibodies above to the MERS-CoV S2 antigen composed of the amino acids 757 to 1275 of the spike protein. -
FIG. 5a is a set of graphs illustrating the neutralizing ability of 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies against pseudovirus using the spike protein of MERS-CoV Erasmus strain. -
FIG. 5b is a set of graphs illustrating the neutralizing ability of 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies against pseudovirus using the spike protein of MERS-CoV Bisha 1 strain. -
FIG. 6a is a set of graphs illustrating the neutralizing ability of 77-A5, 77-A6, 90-A3, 90-A9, 90-B2 and 90-B7 antibodies against MERS-CoV. -
FIG. 6b is a set of graphs illustrating the neutralizing ability of 90-C4, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies against MERS-CoV. -
FIG. 7 is a graph illustrating the morphology of the antibodies analyzed by SEC-HPLC. -
FIG. 8a is a set graphs illustrating the antigen-antibody binding affinity investigated by SPR (Surface Plasmon Resonance) assay using S1 antigen. -
FIG. 8b is a set graphs illustrating the antigen-antibody binding affinity investigated by SPR (Surface Plasmon Resonance) assay using RBD antigen. -
FIG. 9a is a set of graphs illustrating the thermo-stability of 77-A5 and 77-A6 antibodies investigated by PTS (Protein Thermal Shift) assay. -
FIG. 9b is a set of graphs illustrating the thermo-stability of 90-B2 and 90-B7 antibodies investigated by PTS (Protein Thermal Shift) assay. -
FIG. 9c is a set of graphs illustrating the thermo-stability of 90-F1, and 90-F2 antibodies investigated by PTS (Protein Thermal Shift) assay. - Hereinafter, the present invention is described in detail.
- The present invention provides a heavy chain variable region of the monoclonal antibody binding specifically to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21.
- The spike protein above can be a polypeptide composed of any sequence known to those in the art. The polypeptide above can be a variant or a fragment of an amino acid sequence having a different sequence made by deletion, insertion, substitution or combination thereof as long as it does not affect the protein function. The exchange of amino acids in a protein or a peptide, without changing the overall molecular activity, has been well-informed to those in the art. The most common exchanges are between the amino acid residues Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Thy/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly. In some cases, such modifications as phosphorylation, sulfation, acrylation, glycosylation, methylation, and farnesylation can be occurred. In an example of the present invention, the spike protein can be composed of the amino acid sequence represented by SEQ. ID. NO: 23.
- The said heavy chain variable region can specifically bind to the 1st to 757th amino acid sites from the N-terminus of the spike protein of MERS-CoV. Among the heavy chain variable regions, the heavy chain variable region of the monoclonal antibody whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 15, 17, 19, or NO: 21 can bind specifically to the 377th to 588th amino acid sites from the N-terminus of the spike protein of MERS-CoV.
- In a preferred embodiment of the present invention, the present inventors prepared 24 kinds of monoclonal antibodies binding specifically to the spike protein of MERS-CoV. Among them, 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies were confirmed to have excellent adhesion to the full-length spike protein and S1 antigen of MERS-CoV (see
FIGS. 1 and 2 ). 90-F1, 90-E5, 90-E6, 90-F2, 77-A5, and 77-A6 antibodies were confirmed to have excellent adhesion to the RBD antigen of MERS-CoV (seeFIG. 3 ). - The present invention also provides a gene encoding the heavy chain variable region of the monoclonal antibody; a recombinant vector containing the gene above; and a host cell introduced with the gene or the recombinant vector above.
- The heavy chain variable region above can be characterized by the description above. For example, the heavy chain variable region can be the heavy chain variable region of the monoclonal antibody binding specifically to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21.
- The gene above includes not only a sequence encoding the heavy chain variable region but also a polynucleotide having the same nucleotide sequence substantially identical to the gene and a fragment thereof. The polynucleotide having the same nucleotide sequence substantially identical to the gene can have at least 80%, preferably 90% s, and more preferably at least 95% homology with the polypeptide of the present invention. As described above, the polynucleotide of the present invention can include a variant in which one or more nucleotide sequences are substituted, deleted or inserted, as long as the variant encode a protein having the equivalent activity.
- The said vector is a recombinant vector capable of expressing a target peptide in a desired host cell, which indicates a gene construct containing a necessary regulatory element operably linked thereto in order to express the gene insert. The vector includes such expression regulatory elements as initiation codon, termination codon, promoter, and operator, etc. At this time, the initiation codon and termination codon are generally considered as a part of the nucleotide encoding a polypeptide and they have to be in frame with the coding sequence so as to be functioning in a subject when the gene construct is inserted.
- The term “operably linked” herein in this invention indicates a state in which a nucleic acid expression control sequence and a nucleic acid sequence encoding a target protein or RNA are functionally linked to perform a general function. For example, a promoter can be operably linked to a nucleic acid sequence encoding a protein or RNA, which affects the expression of the coding sequence. The operable linkage can be achieved by using the genetic recombination technique which is well-known to those in the art. The site-specific DNA cleavage and linkage can be accomplished by using the enzyme well known to those in the art.
- The vector system of the present invention can be constructed through various methods known to those in the art, and a specific method for this is disclosed in “Sambrook, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001)”.
- The vector of the present invention can be constructed as a typical cloning vector or an expression vector. Also, the vector of the present invention can be constructed by using a prokaryotic cell or a eukaryotic cell as a host cell. For example, when the vector of the present invention is an expression vector and a prokaryotic cell is used as a host cell, it generally includes a strong promoter capable of promoting transcription (for example, tac promoter, lac promoter, lacUV5 promoter, lpp promoter, pL promoter, pR promoter, rac5 promoter, amp promoter, recA promoter, SP6 promoter, trp promoter, and T7 promoter), a ribosome binding site for initiation of translation, and a transcription/translation termination sequence. When E. coli (for example, HB101, BL21, DH5α, etc) is used as a host cell, the promoter and operator region of E. coli tryptophan biosynthesis pathway (Yanofsky, C., J. Bacteriol., 158:1018-1024(1984)) and the pL promoter of phage (pL promoter, Herskowitz, I. and Hagen, D., Ann. Rev. Genet., 14:399-445(1980)) can be used as a regulatory region. When a Bacillus bacterium is used as a host cell, a promoter of a toxin protein gene of Bacillus thuringiensis (Appl. Environ. Microbiol. 64:3932-3938(1998); Mol. Gen. Genet. 250:734-741(1996)) or any promoter capable of expressing in Bacillus can be used as a regulatory region.
- The vector usable in this invention can be constructed by manipulating plasmids (for example, pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8/9, pUC6, pBD9, pHC79, pIJ61, pLAFR1, pHV14, pGEX series, pET series, pRSET, pBluescript, pGEX2T, pCR1, pMB9, RP4, and pUC19 etc.), phages (for example, gt4.B, -Charon, Ez1, and M13) or viruses (for example, SV40 etc.) frequently used in this field.
- When the vector of the invention is an expression vector and the host cell is an eukaryotic cell, a promoter originated from a mammalian cell genome (for example, metallothionine promoter, γ-actin promoter, human hemoglobin promoter, and human muscle creatine promoter) or a promoter originated from a mammalian virus (for example, bovine papulardermatitis virus promoter, adeno-associated virus promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus promoter, HSV tk promoter, mouse mammary tumor virus (MMTV) promoter, HIV LTR promoter, moloney virus promoter, Epstein-Barr virus (EBV) promoter, tobacco mosaic virus promoter, and roas sarcoma virus (RSV) promoter) can be used and a polyadenylation sequence is generally included therein as a transcription termination sequence.
- The vectors of the present invention can be fused with other sequences to facilitate the purification of the antibodies expressed therefrom. The sequences adequate for the fusion are exemplified by glutathione S-transferase, maltose binding protein, FLAG, and 6× His, etc.
- Since the protein expressed by the vector of the present invention is an antibody, the expressed antibody can be easily purified through a protein A column without any additional sequence for the purification.
- The vector above can also include a selection marker. The selection marker herein is a marker for the selection of a transformed microorganism or a recombinant vector, which can be used to give selectable phenotypes such as drug resistance, nutritional requirements, resistance to cytotoxic agents, or surface protein expression. When a vector containing the selection marker is used, only those cells expressing the selection marker can survive in the selective medium, so that the transformed cells can be easily selected. Any selection marker that can be used in the conventional art can be used. For example, ampicillin, gentamycin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin or tetracycline can be used as a selection marker herein.
- Various host cells can be used for the expression of the heavy chain variable region of the monoclonal antibody according to the present invention. For example, the host cells can be prokaryotic cells such as Escherichia sp., Bacillus sp., Streptomyces sp., Pseudomonas sp., Proteus sp., or Staphylococcus sp., fungi such as Aspergillus sp., yeasts such as Pichia sp., Saccharomyces sp., Schizosaccharomyces sp., or Neurospora sp., other lower eukaryotic cells, or eukaryotic sells such as animal cells and plant cells.
- As a method of introducing the recombinant vector of the invention into a host cell and transforming it, the conventional gene manipulation method can be used. For example, as a physical method, microinjection, liposome dependent method, direct DNA uptake, receptor-mediated DNA transfer, Ca++-directed DNA transfer, or virus-mediated gene transfer can be used.
- In a preferred embodiment of the present invention, the present inventors prepared monoclonal antibodies binding specifically to the spike protein of MERS-CoV. Among them, 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies were confirmed to have excellent adhesion to the full-length spike protein and S1 antigen of MERS-CoV (see
FIGS. 1 and 2 ). 90-F1, 90-E5, 90-E6, 90-F2, 77-A5, and 77-A6 antibodies were confirmed to have excellent adhesion to the RBD antigen of MERS-CoV (seeFIG. 3 ). - The present invention also provides a composition for the prevention, treatment or diagnosis of Middle East respiratory syndrome comprising the heavy chain variable region of the monoclonal antibody of the invention.
- The heavy chain variable region above can be characterized by the description above. For example, the heavy chain variable region can be the heavy chain variable region of the monoclonal antibody binding specifically to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21.
- The composition for the treatment of MERS of the present invention can be administered as an independent drug or can be co-administered with other drugs. In the case of co-treatment, it can be administered simultaneously together with the conventional drug or stepwise.
- The composition comprising the heavy chain variable region of the monoclonal antibody above can be used for the treatment of virus infection by introducing into a living body in the form of the antibody-drug conjugate. At this time, the drug can be a chemotherapeutic agent, a radionuclide, an immunotherapeutic agent, a cytokine, a chemokine, a toxin, a biological agent, or an enzyme inhibitor. An example of the method to bind an antibiotic to an antibody is explained in the following references: G. Gregoriadies, ed., Academic Press London, (1979); Arnon et al., Recent Results in Cancer Res., 75: 236 (1980); and Moolton et al., Immunolog. Res., 62:47 (1982).
- The drug that is preferred for the coupling with the antibody of the present invention include antibiotics, antiparasitic, antifungal, and related agents such as, for example, sulfonamide, penicillin and cephalosporin, aminoglycoside, tetracycline, chloramphenicol, piperazine, chloroquine, diaminopyridine, metroniazide, isoniazid, rifampin, streptomycin, sulfone, erythromycin, polymyxin, nistatin, amphotericin, 5-fluorocytosine, 5-iodo-2′-deoxyuridine, 1-adamanthamine, adenine arabinoside, ammanidin, ribavirin or azatrimidine (AZT). The conditions appropriate and preferred for delivering a drug to a specific target are explained in Trouet et al., Plenum Press, New York and London, 19-30 (1982). The immunoregulator usable as a drug in the form of the antibody-drug conjugate can be a lymphokine or a cytokine, but not always limited thereto.
- The composition for the prevention or treatment of MERS of the present invention can include the heavy chain variable region of the monoclonal antibody of the invention as an active ingredient at the concentration of 10-95 weight % by the total weight of the composition. The composition of the present invention can include, in addition to the active ingredient, one or more effective ingredients having the same or similar function to the active ingredient.
- The composition for the prevention or treatment of MERS of the present invention can include any generally used carrier, diluent, excipient, or a combination of at least two of those. The pharmaceutically acceptable carrier can be any carrier that is able to deliver the composition of the present invention in a living body without limitation, which is exemplified by the compounds described in Merck Index, 13th ed., Merck & Co. Inc., such as saline, sterilized water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, liposome and a mixture comprising one or more of those components. If necessary, a general additive such as antioxidant, buffer, and bacteriostatic agent can be additionally added.
- The composition of the present invention can be prepared for oral or parenteral administration by mixing with generally used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactant. Solid formulations for oral administration are tablets, pills, powders, granules, capsules, and troches. These solid formulations are prepared by mixing the composition of the present invention with one or more suitable excipients such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. Lubricants such as magnesium stearate and talc can also be included therein. Liquid formulations for oral administrations are suspensions, solutions, emulsions and syrups, and the above-mentioned formulations can contain various excipients such as wetting agents, sweeteners, aromatics and preservatives.
- Formulations for parenteral administration are sterilized aqueous solutions, water-insoluble excipients, suspensions, and emulsions.
- Water insoluble excipients and suspensions can contain propylene glycol, polyethylene glycol, vegetable oil like olive oil, injectable ester like ethylolate, etc.
- The composition for the prevention or treatment of MERS of the present invention can be administered orally or parenterally and the parenteral administration includes intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, intramuscular injection, and intra-thoracic injection.
- The composition for the prevention or treatment of MERS of the present invention is administered in a pharmaceutically effective dose. The effective dose can be determined by considering many factors such as the type of disease, severity of the disease, activity of the drug, sensitivity to the drug, administration frequency and pathway, excretion, term of treatment, co-treatment drug and other factors regarded as relevant in the medicinal field. In the case of co-treatment, the composition of the invention can be administered simultaneously together with the other drugs or stepwise.
- For the preferred effect, the amount of the active ingredient included in the composition of the present invention can be 0.001˜10,000 mg/kg, specifically 0.1˜5 g/kg. The administration frequency can be once a day or a few times a day.
- The diagnostic composition of the present invention indicates a major tool used for the diagnosis of a target disease, which can include the materials useful for diagnosing MERS-CoV according to the purpose of the invention. The diagnostic method can include the step of contacting an antibody or an antibody fragment with a sample.
- The sample herein can be sputum, cells or a tissues taken from nasal cavity, sinus cavity, salivary gland, lung, liver, pancreas, kidney, ear, eye, placenta, digestive tract, heart, ovary, pituitary, adrenal, thyroid, brain or skin, urine, whole blood, serum, plasma, feces, cell culture supernatant, or ruptured eukaryotic cells.
- The formation of the sample-antibody conjugate can be detected by colormetric method, electrochemical method, fluorimetric method, luminometry, particle counting method, visual assessment, or scintillation counting method.
- The detection is to detect the sample-antibody conjugate, for which various markers can be used. As the marker, an enzyme, a fluorescent material, a ligand, a luminescent material, a microparticle or a radioactive isotope can be used.
- The enzyme usable as a detection marker is exemplified by acetylcholinesterase, alkaline phosphatase, γ-D-galactosidase, horseradish peroxidase, and γ-lactamase. The fluorescent material usable as a detection marker can be fluorescein, Eu3+, Eu3+ chelate, or cryptate. As the ligand, a biotin derivative can be used. As the luminescent material, acridinium ester and an isoluminol derivative can be used. Colloidal gold and colored latex can be used as the microparticle, and 57Co, 3H, 125I, and 125I-Bonton Hunter reagent can be used as the radioactive isotope.
- In a preferred embodiment of the present invention, the present inventors prepared monoclonal antibodies binding specifically to the spike protein of MERS-CoV. Among them, 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies were confirmed to have excellent adhesion to the full-length spike protein and S1 antigen of MERS-CoV (see
FIGS. 1 and 2 ). 90-F1, 90-E5, 90-E6, 90-F2, 77-A5, and 77-A6 antibodies were confirmed to have excellent adhesion to the RBD antigen of MERS-CoV (seeFIG. 3 ). 77-A5, 77-A6, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies exhibited neutralizing ability against MERS pseudovirus and MERS-CoV, and 90-B2 and 90-B7 antibodies showed neutralizing ability only against MERS-CoV (seeFIGS. 5a ,FIG. 5b ,FIG. 6a andFIG. 6b ). The monoclonal antibodies above were confirmed to be in the form of a certain monomer (seeFIG. 7 ) and have excellent stability (seeFIG. 9a to 9c). - The present invention also provides a kit for the detection or quantification of an antigen of Middle East respiratory syndrome by using the antibody and protein comprising the heavy chain variable region of the monoclonal antibody of the invention.
- The heavy chain variable region above can be characterized by the description above. For example, the heavy chain variable region can be the heavy chain variable region of the monoclonal antibody binding specifically to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21.
- The said kit can be prepared by the conventional method well known to those in the art. The kit can additionally include a buffer, a stabilizer, and an inactive protein. The kit can be used in the following method: fluorescence method performed by detecting fluorescence of the fluorescent material attached as a detection marker to investigate the amount of the detection reagent, high throughput screening (HTS) system through radiation method performed by detecting radiation of the radioactive isotope attached as a detection marker, surface plasmon resonance (SPR) method to measure the surface plasmon resonance change in real time without labeling a detection marker, or surface plasmon resonance imaging (SPRI) method for imaging and verifying SPR system.
- In a preferred embodiment of the present invention, the present inventors prepared monoclonal antibodies binding specifically to the spike protein of MERS-CoV. Among them, 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies were confirmed to have excellent adhesion to the full-length spike protein and S1 antigen of MERS-CoV (see
FIGS. 1 and 2 ). 90-F1, 90-E5, 90-E6, 90-F2, 77-A5, and 77-A6 antibodies were confirmed to have excellent adhesion to the RBD antigen of MERS-CoV (seeFIG. 3 ). 77-A5, 77-A6, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies exhibited neutralizing ability against MERS pseudovirus and MERS-CoV, and 90-B2 and 90-B7 antibodies showed neutralizing ability only against MERS-CoV (seeFIGS. 5a ,FIG. 5b ,FIG. 6a andFIG. 6b ). The monoclonal antibodies above were confirmed to be in the form of a certain monomer (seeFIG. 7 ) and have excellent stability (seeFIG. 9a toFIG. 9c ). - The present invention also provides a method for preventing, treating or diagnosing Middle East respiratory syndrome comprising a step of administering the heavy chain variable region of the monoclonal antibody of the invention to a subject.
- The heavy chain variable region above can be characterized by the description above. For example, the heavy chain variable region can be the heavy chain variable region of the monoclonal antibody binding specifically to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21.
- In addition, the subject can be a mammal, specifically a human.
- The heavy chain variable region of the present invention can be administered orally or parenterally and the parenteral administration includes intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, intramuscular injection, and intra-thoracic injection.
- The heavy chain variable region of the present invention is administered in a pharmaceutically effective dose. The effective dose can be determined by considering many factors such as the type of disease, severity of the disease, activity of the drug, sensitivity to the drug, administration frequency and pathway, excretion, term of treatment, co-treatment drug and other factors regarded as relevant in the medicinal field. In the case of co-treatment, the heavy chain variable region of the invention can be administered simultaneously together with the other drugs or stepwise.
- For the preferred effect, the amount of the active ingredient included in the heavy chain variable region of the present invention can be 0.001-10,000 mg/kg, specifically 0.1-5 g/kg. The administration frequency can be once a day or a few times a day.
- The heavy chain variable region of the present invention indicates a major tool used for the diagnosis of a target disease, which can include the materials useful for diagnosing MERS-CoV according to the purpose of the invention. The diagnostic method can include the step of contacting an antibody or an antibody fragment with a sample.
- The sample herein can be sputum, cells or a tissues taken from nasal cavity, sinus cavity, salivary gland, lung, liver, pancreas, kidney, ear, eye, placenta, digestive tract, heart, ovary, pituitary, adrenal, thyroid, brain or skin, urine, whole blood, serum, plasma, feces, cell culture supernatant, or ruptured eukaryotic cells.
- The formation of the sample-antibody conjugate can be detected by colormetric method, electrochemical method, fluorimetric method, luminometry, particle counting method, visual assessment, or scintillation counting method.
- The detection is to detect the sample-antibody conjugate, for which various markers can be used. As the marker, an enzyme, a fluorescent material, a ligand, a luminescent material, a microparticle or a radioactive isotope can be used.
- The enzyme usable as a detection marker is exemplified by acetylcholinesterase, alkaline phosphatase, γ-D-galactosidase, horseradish peroxidase, and γ-lactamase. The fluorescent material usable as a detection marker can be fluorescein, Eu3+, Eu3+ chelate, or cryptate. As the ligand, a biotin derivative can be used. As the luminescent material, acridinium ester and an isoluminol derivative can be used. Colloidal gold and colored latex can be used as the microparticle, and 57Co, 3H, 125I, and 125I-Bonton Hunter reagent can be used as the radioactive isotope.
- The present invention also provides a use of the heavy chain variable region of the monoclonal antibody of the invention for the manufacture of a medicament for preventing, treating or diagnosing Middle East respiratory syndrome.
- The heavy chain variable region above can be characterized by the description above.
- The present invention also provides a light chain variable region of the monoclonal antibody specifically binding to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- The spike protein above can be characterized by the description above. In a preferred embodiment of the present invention, the spike protein can be composed of the amino acid sequence represented by SEQ. ID. NO: 23.
- The said light chain variable region can specifically bind to the 1st to 757th amino acid sites from the N-terminus of the spike protein of MERS-CoV. Among the light chain variable regions, the light chain variable region of the monoclonal antibody whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 16, 18, 20, or NO: 22 can bind specifically to the 377th to 588th amino acid sites from the N-terminus of the spike protein of MERS-CoV.
- The present invention also provides a gene encoding the light chain variable region of the monoclonal antibody of the invention; a recombinant vector containing the gene above; and a host cell introduced with the gene or the recombinant vector above.
- The light chain variable region above can be characterized by the description above. For example, the light chain variable region can be the light chain variable region of the monoclonal antibody binding specifically to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- The gene above is characterized by the description above.
- The said vector is a recombinant vector capable of expressing a target peptide in a desired host cell, which indicates a gene construct containing a necessary regulatory element operably linked thereto in order to express the gene insert.
- Various host cells can be used in order to express the light chain variable region of the monoclonal antibody according to the present invention. The usable host cells are characterized by the description above.
- As a method of introducing the recombinant vector of the invention into a host cell and transforming it, the conventional gene manipulation method can be used. For example, as a physical method, microinjection, liposome dependent method, direct DNA uptake, receptor-mediated DNA transfer, Ca++-directed DNA transfer, or virus-mediated gene transfer can be used.
- The present invention also provides a composition for the prevention, treatment or diagnosis of Middle East respiratory syndrome comprising the light chain variable region of the monoclonal antibody of the invention.
- The light chain variable region above can be characterized by the description above. For example, the light chain variable region can be the light chain variable region of the monoclonal antibody binding specifically to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- The composition for the prevention or treatment of the invention is characterized by the description above.
- The diagnostic composition of the present invention indicates a major tool used for the diagnosis of a target disease, which can include the materials useful for diagnosing MERS-CoV according to the purpose of the invention. The diagnostic method can include the step of contacting an antibody or an antibody fragment with a sample. The sample herein can be sputum, cells or a tissues taken from nasal cavity, sinus cavity, salivary gland, lung, liver, pancreas, kidney, ear, eye, placenta, digestive tract, heart, ovary, pituitary, adrenal, thyroid, brain or skin, urine, whole blood, serum, plasma, feces, cell culture supernatant, or ruptured eukaryotic cells.
- The present invention also provides a kit for the detection or quantification of an antigen of Middle East respiratory syndrome by using the antibody and protein comprising the light chain variable region of the monoclonal antibody of the invention.
- The light chain variable region above can be characterized by the description above. For example, the light chain variable region can be the light chain variable region of the monoclonal antibody binding specifically to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- The kit above is characterized by the description above. For example, it can be prepared by the conventional method known to those in the art, and can additionally include a buffer, a stabilizer, and an inactive protein, etc. The kit can be used in the following method: fluorescence method performed by detecting fluorescence of the fluorescent material attached as a detection marker to investigate the amount of the detection reagent, high throughput screening (HTS) system through radiation method performed by detecting radiation of the radioactive isotope attached as a detection marker, surface plasmon resonance (SPR) method to measure the surface plasmon resonance change in real time without labeling a detection marker, or surface plasmon resonance imaging (SPRI) method for imaging and verifying SPR system.
- The present invention also provides a method for preventing, treating or diagnosing Middle East respiratory syndrome comprising a step of administering the light chain variable region of the monoclonal antibody of the invention to a subject.
- The light chain variable region above can be characterized by the description above. For example, the light chain variable region can be the light chain variable region of the monoclonal antibody binding specifically to the spike protein of MERS-CoV whose complementarity determining region (CDR) is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- In addition, the subject can be a mammal, specifically a human.
- The light chain variable region of the present invention can be administered orally or parenterally and the parenteral administration includes intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, intramuscular injection, and intra-thoracic injection.
- The light chain variable region of the present invention is administered in a pharmaceutically effective dose. The effective dose can be determined by considering many factors such as the type of disease, severity of the disease, activity of the drug, sensitivity to the drug, administration frequency and pathway, excretion, term of treatment, co-treatment drug and other factors regarded as relevant in the medicinal field. In the case of co-treatment, the light chain variable region of the invention can be administered simultaneously together with the other drugs or stepwise.
- For the preferred effect, the amount of the active ingredient included in the light chain variable region of the present invention can be 0.001-10,000 mg/kg, specifically 0.1-5 g/kg. The administration frequency can be once a day or a few times a day.
- The light chain variable region of the present invention indicates a major tool used for the diagnosis of a target disease, which can include the materials useful for diagnosing MERS-CoV according to the purpose of the invention. The diagnostic method can include the step of contacting an antibody or an antibody fragment with a sample.
- The sample herein can be sputum, cells or a tissues taken from nasal cavity, sinus cavity, salivary gland, lung, liver, pancreas, kidney, ear, eye, placenta, digestive tract, heart, ovary, pituitary, adrenal, thyroid, brain or skin, urine, whole blood, serum, plasma, feces, cell culture supernatant, or ruptured eukaryotic cells.
- The formation of the sample-antibody conjugate can be detected by colormetric method, electrochemical method, fluorimetric method, luminometry, particle counting method, visual assessment, or scintillation counting method.
- The detection is to detect the sample-antibody conjugate, for which various markers can be used. As the marker, an enzyme, a fluorescent material, a ligand, a luminescent material, a microparticle or a radioactive isotope can be used.
- The enzyme usable as a detection marker is exemplified by acetylcholinesterase, alkaline phosphatase, γ-D-galactosidase, horseradish peroxidase, and γ-lactamase. The fluorescent material usable as a detection marker can be fluorescein, Eu3+, Eu3+ chelate, or cryptate. As the ligand, a biotin derivative can be used. As the luminescent material, acridinium ester and an isoluminol derivative can be used. Colloidal gold and colored latex can be used as the microparticle, and 57Co, 3H, 125I, and 125I-Bonton Hunter reagent can be used as the radioactive isotope.
- The present invention also provides a use of the light chain variable region of the monoclonal antibody of the invention for the manufacture of a medicament for preventing, treating or diagnosing Middle East respiratory syndrome.
- The light chain variable region above can be characterized by the description above.
- The present invention also provides a monoclonal antibody specifically binding to the spike protein of MERS-CoV containing a heavy chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21, and a light chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- The spike protein above can be characterized by the description above. In a preferred embodiment of the present invention, the spike protein can be composed of the amino acid sequence represented by SEQ. ID. NO: 23. The light chain variable region and the heavy chain variable region can be characterized by the description above.
- The monoclonal antibody is an antibody produced by a single antibody-forming cell, which has a uniform primary structure (amino acid sequence). The monoclonal antibody recognizes only one antigenic determinant and is generally produced by culturing the hybridoma cells prepared by the fusion of cancer cells and antibody producing cells. This antibody also can be produced by using other recombinant protein expressing host cells using the obtained antibody gene sequence.
- The present invention also provides a gene encoding the monoclonal antibody of the invention; a recombinant vector containing the gene above; and a host cell introduced with the gene or the recombinant vector above.
- The monoclonal antibody above can be characterized by the description above. For example, the monoclonal antibody can be the antibody binding specifically to the spike protein of MERS-CoV containing a heavy chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21, and a light chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- The gene above is characterized by the description above.
- The said vector is a recombinant vector capable of expressing a target peptide in a desired host cell, which indicates a gene construct containing a necessary regulatory element operably linked thereto in order to express the gene insert.
- Various host cells can be used in order to express the monoclonal antibody according to the present invention. The usable host cells are characterized by the description above.
- As a method of introducing the recombinant vector of the invention into a host cell and transforming it, the conventional gene manipulation method can be used. For example, as a physical method, microinjection, liposome dependent method, direct DNA uptake, receptor-mediated DNA transfer, Ca++-directed DNA transfer, or virus-mediated gene transfer can be used.
- The present invention also provides a composition for the prevention, treatment or diagnosis of Middle East respiratory syndrome comprising the monoclonal antibody of the invention.
- The monoclonal antibody above can be characterized by the description above. For example, the monoclonal antibody can be the antibody binding specifically to the spike protein of MERS-CoV containing a heavy chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21, and a light chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- The composition for the prevention or treatment of the invention is characterized by the description above.
- The diagnostic composition of the present invention indicates a major tool used for the diagnosis of a target disease, which can include the materials useful for diagnosing MERS-CoV according to the purpose of the invention. The diagnostic method can include the step of contacting an antibody or an antibody fragment with a sample. The sample herein can be sputum, cells or a tissues taken from nasal cavity, sinus cavity, salivary gland, lung, liver, pancreas, kidney, ear, eye, placenta, digestive tract, heart, ovary, pituitary, adrenal, thyroid, brain or skin, urine, whole blood, serum, plasma, feces, cell culture supernatant, or ruptured eukaryotic cells.
- The present invention also provides a kit for the detection or quantification of an antigen of Middle East respiratory syndrome comprising the monoclonal antibody of the invention.
- The monoclonal antibody above can be characterized by the description above. For example, the monoclonal antibody can be the antibody binding specifically to the spike protein of MERS-CoV containing a heavy chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21, and a light chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- The kit above is characterized by the description above. For example, it can be prepared by the conventional method known to those in the art, and can additionally include a buffer, a stabilizer, and an inactive protein, etc. The kit can be used in the following method: fluorescence method performed by detecting fluorescence of the fluorescent material attached as a detection marker to investigate the amount of the detection reagent, high throughput screening (HTS) system through radiation method performed by detecting radiation of the radioactive isotope attached as a detection marker, surface plasmon resonance (SPR) method to measure the surface plasmon resonance change in real time without labeling a detection marker, or surface plasmon resonance imaging (SPRI) method for imaging and verifying SPR system.
- The present invention also provides a method for preventing, treating or diagnosing Middle East respiratory syndrome comprising a step of administering the monoclonal antibody of the invention to a subject.
- The monoclonal antibody above can be characterized by the description above. For example, the monoclonal antibody can be the antibody binding specifically to the spike protein of MERS-CoV containing a heavy chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or NO: 21, and a light chain variable region whose complementarity determining region is composed of the amino acid sequence represented by SEQ. ID. NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or NO: 22.
- In addition, the subject can be a mammal, specifically a human.
- The monoclonal antibody of the present invention can be administered orally or parenterally and the parenteral administration includes intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, intramuscular injection, and intra-thoracic injection.
- The monoclonal antibody of the present invention is administered in a pharmaceutically effective dose. The effective dose can be determined by considering many factors such as the type of disease, severity of the disease, activity of the drug, sensitivity to the drug, administration frequency and pathway, excretion, term of treatment, co-treatment drug and other factors regarded as relevant in the medicinal field. In the case of co-treatment, The monoclonal antibody of the invention can be administered simultaneously together with the other drugs or stepwise.
- For the preferred effect, the amount of the active ingredient included in the monoclonal antibody of the present invention can be 0.001˜10,000 mg/kg, specifically 0.1˜5 g/kg. The administration frequency can be once a day or a few times a day.
- The monoclonal antibody of the present invention indicates a major tool used for the diagnosis of a target disease, which can include the materials useful for diagnosing MERS-CoV according to the purpose of the invention. The diagnostic method can include the step of contacting an antibody or an antibody fragment with a sample.
- The sample herein can be sputum, cells or a tissues taken from nasal cavity, sinus cavity, salivary gland, lung, liver, pancreas, kidney, ear, eye, placenta, digestive tract, heart, ovary, pituitary, adrenal, thyroid, brain or skin, urine, whole blood, serum, plasma, feces, cell culture supernatant, or ruptured eukaryotic cells.
- The formation of the sample-antibody conjugate can be detected by colormetric method, electrochemical method, fluorimetric method, luminometry, particle counting method, visual assessment, or scintillation counting method.
- The detection is to detect the sample-antibody conjugate, for which various markers can be used. As the marker, an enzyme, a fluorescent material, a ligand, a luminescent material, a microparticle or a radioactive isotope can be used.
- The enzyme usable as a detection marker is exemplified by acetylcholinesterase, alkaline phosphatase, γ-D-galactosidase, horseradish peroxidase, and γ-lactamase. The fluorescent material usable as a detection marker can be fluorescein, Eu3+, Eu3+ chelate, or cryptate. As the ligand, a biotin derivative can be used. As the luminescent material, acridinium ester and an isoluminol derivative can be used. Colloidal gold and colored latex can be used as the microparticle, and 57Co, 3H, 125I, and 125I-Bonton Hunter reagent can be used as the radioactive isotope.
- The present invention also provides a use of the monoclonal antibody of the invention for the manufacture of a medicament for preventing, treating or diagnosing Middle East respiratory syndrome.
- The monoclonal antibody above can be characterized by the description above.
- Practical and presently preferred embodiments of the present invention are illustrative as shown in the following Examples.
- However, it will be appreciated that those skilled in the art, on consideration of this disclosure, may make modifications and improvements within the spirit and scope of the present invention.
- In the period between May and July 2015 when MERS occurred in Korea, blood samples were taken from patients with early stage MERS. Peripheral blood mononuclear cells (PBMCs) were isolated from those blood samples by the conventional method, which were cryopreserved. B cells having MERS antibody were separated as single cells (single cell sorting) from the PBMCs isolated by FACS using the MERS-CoV spike trimer protein probe (PE fluorescent dye), anti-human IgG-FITC and anti-human CD20 IgG-Cy55PerCP, provided by NIH/NIAID/VRC, USA. Unnecessary immune cells except B cells were negatively selected by attaching CD3, CD4, CD8 and CD14 markers and removed by FACS. CDR regions of the heavy chain, kappa light chain and lambda light chain of the antibody gene separated from the B cells obtained from patients with early phase MERS were amplified by PCR, and the sequences were confirmed. The nucleotide sequence appropriate for the immunoglobulin antibody expression was examined by using a web-based IMGT (International Immunogenetics Information systems, http://www.imgt.org) program. CDR regions of the heavy chain, kappa light chain and lambda light chain of the antibody were cloned in pVRC vector comprising mouse IgM signal peptide and IgG constant region provided by NIH/NIAID/VRC, USA. Then, Expi293F cells were transfected with the prepared antibody plasmid. 5 days later, the cell culture fluid was obtained, from which the antibody was prepared by purifying with protein G agarose column.
- The binding affinity of 24 kinds of the antibodies prepared in Example 1 to the full-length spike trimer antigen of MERS-CoV, which is composed of
amino acids 1 to 1275 from the N-terminus of the spike protein and is lack of the transmembrane region, was confirmed. The adhesion was compared among the monoclonal antibodies prepared in Example 1, the human anti-S1 monoclonal antibodies A2 and A10, the human anti-RBD monoclonal antibody C2, the mouse anti-S2 monoclonal antibody G4, and the mouse anti-S1 monoclonal antibody G2, developed by NIH, USA. - Particularly, MERS-CoV full spike trimer antigen was loaded in MaxiSorp 96-well plate (Nunc) at the concentration of 0.2 μg/100 μ PBS/well, followed by reaction at 4° C. for a day. Upon completion of the reaction, the reaction solution was eliminated, followed by blocking with a blocking solution containing 5% skim milk and 2% BSA in PBST at room temperature for 1 hour. Next, the antibody prepared in Example 1 was diluted in the blocking solution at the concentration of 10, 2.5, 0.625, 0.15625, 0.039, 0.009, 0.002, 0.0006, or 0.0001 μg/m, which was loaded in the plate coated with the full spike trimer antigen above, followed by reaction at room temperature for 1 hour. The plate was washed with
PBST 6 times, to which rabbit anti-human IgG H&L-HRP (horse radish peroxidase) secondary antibody was added, followed by reaction for 1 hour. Anti-mouse IgG-HRP secondary antibody was added to the well containing G2 and G4 antibodies, followed by reaction for 1 hour. After washing withPBST 6 times, 100 μ of TMB solution was added to each well, followed by reaction at room temperature for 30 minutes with blocking light. Upon completion of the reaction, 100 μ of stop solution (Enzygost) was added to each well. Then, OD450 was measured to investigate the antibody adhesion to antigen. -
TABLE 1 CDR amino acid sequences to 11 MERS antibodies CDR sequence of heavy CDR sequence of kappa CDR sequence of lambda Antiboby chain light chain light chain 77-A5 TGVHSQVQLVQSGAEVKKPGS TGSWAQSALTQPPSASGTPGQ SVKVSCKASGGTFRSHAISWV RVTISCSGSSSNIGSNTVNWY RQAPGQGLEWMGGIIPIFASA QQLPGTAPKLLIYSNNQRPSG NYAQKFQGRVTITADESTSTA VPDRFSGSKSGTSASLAISGL YMDLSSLRSDDTAVYYCAKNV QSEDEADYYCAAWDDSLSGHY SPKSYSGRYSISYFYGVDVWG VFGTGTKVTVLGQPKANPTVT QGTTVTVSSA LFPPS (SEQ.ID. NO: 1) (SEQ. ID. NO: 2) 77-A6 TGVHSEVQLLESGGGLVQPGG TGSWAQSALTQPPSVSAAPGQ SLRLSCADSGLTFSSYAMSWV KVTISCSGSSSNIGNNYVSWY RQAPGKGLEWVSAISVSGGST QHLPGTAPKLLIYDNIMRPSG YYSDSVKGRFTISRDNSKNTL IPDRFSGSKSGTSATLGITGL SLQMNSLRAEDTAVYYCVKAR QTGDEADYYCGTWDTSLSAW SIVGPFDYWGQGTLVTVSSAS FGGGTKLTVLGQPKAAPSVTL (SEQ. ID. NO: 3) FPPS (SEQ. ID. NO: 4) 90-A3 TGVHSQVQLVQSGAEVKKPGA TGSNSQAVVTQPPSVSAAPGQ SVKVSCMTSGYTFTSYGISWV KVTISCSGSSSNIGNNYVSWY RQAPGQGLEWMGWISAYNGNT QQLPGTAPKLLIYDNNKRPSG NYAQKLQGRVTMTTDTSTSTA IPDRFSGSKSGTSATLGITGL YMELSSLRSDDTAVYYCARDR QTGDEADYYCGTWDSSLSAW GAYWDCGGDCYLSAFDYWGQG FGGGTKLTVLGQPKAAPSVTL TLVTVSSAS FPPS (SEQ. ID. NO: 5) (SEQ. ID. NO: 6) 90-A9 TGVHSQVQLVQSGAEVKKPGS TGVHSEIVLTQSPGTLSL SVKVSCKASGGTFSSFPISWV SPGERATLSCRASQSVAS RQAPGQGLEWMGGIIPIFGAA SYLAWYQQKPGQAPRLLI NYAQKFQGRVTITADESTSTA YGTSSRATGIPDRFSGSG YMELSSLRSEDTAVYYCAENY SGADFTLTISRLEPEDFA EEIWIPAIMNFGYWGQGTLVT VYYCQQYGTSPLTFGGGT VSSAS KVEIK (SEQ. ID. NO: 7) (SEQ. ID. NO: 8) 90-B2 TGVHSQVQLQESGPGLVKPSE TGVHSEIVLTQSPATLSL TLSLTCTVSGGSISSSSYYWG SPGGRATLSCRASQSVSR WIRQPPGKGLEWIGSIYYSGN YLAWYQQKPGRAPRLLIY TYYNPSLKSRVTISVDTSKNK DASNRAPGIPARFSGSGS FSLRLSSVTAADTAVYFCARS GTDFTLTISSLEPEDFAV LPHYDSTGYLLYWGQGTLVTV YYCQQRSNWPQTTFGPGT SSAS KVDIKRT (SEQ. ID. NO: 9) (SEQ. ID. NO: 10) 90-B7 TGVHSEVQLLESGGGLVKPGG TGSNSQAVVTQPPSVSAAPGQ SLRLSCAASGFTFGSYSMTWV KVTISCSGSSSNIGNNYVSWY RQAPGKGLEWVSSISSSSSYI QQLPGTAPKLLIYDNNKRPSG YYADSVKGRFTISRDNAKNSL IPDRFSGSKSGTSATLGITGL FLQMNSLRAEDTAVYYCARGN QTGDEADYYCGTWDSSLSAFV GYCSHNSCYKIGVWFDPWGQG FGTGTKVTVLGQPKANPTVTL TLVTVSSAS FPPS (SEQ. ID. NO: 11) (SEQ. ID. NO: 12) 90-C4 TGVHSQVQLQESGPGLVKPSG TGSWAQSALTQPPSVSGAPGQ TLSLTCAVSGGSINSSNWWSW RVTISCTGSSSSIGAGYDVHW VRQPPGKGLEWIGEIYYSGST YQQLPGTAPKLLIYGNSNRPS NYNPSLKSRVTTSVDNSKNQF GVPDRFSGSKSGTSASLAITG SLKLSSVTAADTAVYYCATFD LQAEDEADYYCQSYDSSLSGY SGGYNPNWFDPWGQGTLVTVS VFGTGTKVTVLGQPKANPTVT SAS(SEQ. ID. NO: 13) LFPPS (SEQ. ID. NO: 14) 90-E5 TGVHSQVQLVQSGAEVKKPGS TGSWAQSVLTQPPSVSGAPGQ SVKVSCKASGGTFSSYTINWV RVTISCTGSSSNIGAGYDVHW RQAPGQGLEWMGGIIPIFGTA YQQLPGTAPKVLIYGNSNRPS NYAQKFQGRVTITADASTSTA GVPDRFSGSKSDTSASLAITG YMELSSLRSEDTAVYYCARVL LQAEDEADYYCQSYDSSLSW LRSSSWFSSNWFDPWGQGTLV FGGGTKLTVLGQPKAAPSVTL TVSSAS FPPS (SEQ. ID. NO: 15) (SEQ. ID. NO: 16) 90-E6 TGVHSEVQLVESGGGLVQPGR TGSWAQSVLTQPPSVSAAPGQ SLRLSCAASGFTFDDHAMHWV KVTISCSGSRSNIGNNYVSWY RQAPGKGLEWVSGFSWNSGSI QQLPGTAPKLLIYDNNKRPSG GYADSVKGRFTISRDNAKNSL IPDRFSGSKSGTSATLGITGL YLQMNSLRAEDTALYYCAKDR QTGDEADYYCGTWDSSLNAGV RSDYYFYGMDVWGQGTTVTVS FGGGTKLTVLGQPKAAPSVTL SAS FPPS (SEQ. ID. NO: 17) (SEQ. ID. NO: 18) 90-F1 TGVHSQVQLVQSGAEVKRPGS TGVHSEIVLTQSPATLSL SVKVSCKTSGGTFNNNAINWV SPGERATLSCGASQSVSS RQAPGQGLEWMGGIIPFFGIA SYLAWYQQKPGLAPRLLI KYAQKFQGRVTITADESTSTA YDASSRATGIPDRFSGSG YMELSSLRSEDTAVYYCARDL SGTDFTLTISRLEREDFA PRESSYGSGSYYTHYYAMDVW VYYCQQYGSSPLTFGGGT GQGTTVTVSSAS KVEIKRT (SEQ. ID. NO: 19) (SEQ. ID. NO: 20) 90-F2 TGVHSQVQLVQSGAEVKKPGA TGVHSDIQMTQSPSTLSA SVKVSCKASGYTFITYYMHWV SVGDRVTITCRASQTIST RQAPGQGLEWMGIINPSGGST WLAWYQQKPGKAPKLLIY SYAQKFQGRVTMTRDTSTSTV KASSLESGVPSRFSGSGS YMELSSLRSEDTAVYYCARGA GTEFTLTISSLQPDDFAT VWILDYWGQGTLVTVSSAS YYCQQYNSYSYTFGQGTK (SEQ. ID. NO: 21) LEIKRT (SEQ. ID. NO: 22) - As a result, as shown in
FIG. 1 , among the 24 antibodies, 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies demonstrated excellent adhesion to MERS-CoV full spike trimer antigen, which was greater than that of A2, A10, and G4 antibodies (FIG. 1 ). CDR sequences of 11 kinds of the antibodies demonstrating excellent adhesion to the full spike trimer antigen are shown in Table 1. - The binding affinity of 24 kinds of the antibodies prepared in Example 1 was investigated by the same manner as described in Experimental Example 1-1 except that the MERS-CoV S1 domain composed of
amino acids 1 to 757 from the N-terminus of the spike protein was used as an antigen. - As a result, as shown in
FIG. 2 , among the 24 antibodies, 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies demonstrated excellent adhesion to the S1 antigen, which was greater than that of the A2 and A10 antibodies developed by NIH, USA. In particular, 90-F1, 90-B7, 90-E6, 77-A4, 77-A5, 90-F2, and 77-A6 antibodies demonstrated higher adhesion than that of C2 and G2 antibodies (FIG. 2 ). - The binding affinity of 24 kinds of the antibodies prepared in Example 1 was investigated by the same manner as described in Experimental Example 1-1 except that the MERS-CoV RBD (receptor binding domain) composed of amino acids 377 to 588 from the N-terminus of the spike protein was used as an antigen.
- As a result, as shown in
FIG. 3 , among those 24 antibodies, 90-F1, 90-E5, 90-E6, 90-F2, 77-A5, and 77-A6 antibodies showed higher adhesion to the RBD antigen than that of C2 antibody. The rest of those antibodies did not show adhesion to the RBD antigen (FIG. 3 ). - The binding affinity of 24 kinds of the antibodies prepared in Example 1 was investigated by the same manner as described in Experimental Example 1-1 except that the MERS-CoV S2 domain composed of amino acids 757 to 1275 from the N-terminus of the spike protein was used as an antigen.
- As a result, as shown in
FIG. 4 , all of those 24 antibodies prepared in Example 1 showed very low adhesion to the S2 antigen (FIG. 4 ). - Huh7.5 cell line was treated with trypsin and suspended. The cells were diluted with DMEM (Dulbecco's modified Eagle's medium) containing 10% FBS, which were distributed in a 96-well tissue culture late at the density of 104 cells/100 μ/well, followed by culture for a day. In the meantime, 90 μ of the supernatant of recombinant lentivirus (recombinant MRES pseudovirus expressing luciferase, NIH/NIAID/VRC, USA) containing MERS-CoV spike protein (Erasmus strain or
Bisha 1 strain) and 90 μ of the antibody of Example 1 diluted in cell culture medium at the concentration of 10, 1, 0.1, 0.01, or 0,001 μs/m were mixed with DMEM containing 10% FBS, followed by reaction at 37° C. for 45 minutes, resulting in the preparation of a reaction mixture. The mixture was added to the culture plate (50 μ/well), to which DMEM containing 10% FBS was added (100 μ/well), followed by culture in a 37° C., 5% CO2 incubator for 3 days. After discarding the culture fluid, 1× lysis buffer (Promega, E153A) was added therein at the concentration of 25 μ/well, followed by stirring for 15 minutes to lyse the cells. The lysed cells were added with luciferase substrate reagent (Promega, E151A) (50 μ/well). Fluorescence was measured with a luminometer and neutralizing capacity was calculated by the followingmathematical formula 1. -
Neutralizing Capacity (%)=100−(luciferase signal mean value of antibody-treated pseudovirus/background signal of antibody-non-treated pseudovirus×100) [Mathematical Formula 1] -
TABLE 2 Neutralizing capacity of 11 antibodies Antibody Neutralizing Capacity (%) Conc. (μg/ml) 77-A5 77-A6 90-A3 90-A9 90- B2 10 95.93 99.04 −29.25 −9.72 −152.78 2.5 92.87 99.53 5.01 31.92 −71.75 0.625 67.05 97.96 22.00 18.73 −59.75 0.15625 64.10 92.04 28.44 15.01 −59.65 0.039063 3.16 56.75 2.43 −6.41 −40.74 0.009766 28.89 41.59 −15.18 −1.78 −44.11 0.002441 −3.78 3.81 6.57 −18.34 −25.61 Virus alone 0.00 0.00 0.00 0.00 Antibody Neutralizing Capacity (%) Conc. (μg/ml) 90-B7 90-C4 90-E5 90-E6 90-F1 90- F2 10 −49.92 20.88 91.00 58.10 99.83 98.17 2.5 −9.19 28.48 79.40 66.30 99.65 94.39 0.625 −32.26 −3.31 61.12 44.77 98.55 86.01 0.15625 −30.39 17.46 46.94 41.31 98.56 59.63 0.039063 −21.07 2.43 38.62 41.83 88.45 48.10 0.009766 0.10 −23.37 37.07 10.61 69.87 21.76 0.002441 −9.71 −7.53 38.20 36.45 54.92 48.40 Virus alone 0.00 0.00 15.11 26.03 0.00 0.00 - As a result, as shown in
FIG. 5a ,FIG. 5b and Table 2, 77-A5, 77-A6, 90-E5, 90-E6, 90-F1, and 90-F2 antibodies demonstrated neutralizing capacity against MERS pseudovirus Erasmus strain. Among them, 77-A5, 77-A6, 90-F1, and 90-F2 antibodies showed neutralizing capacity againstMERS pseudovirus Bisha 1 strain as well. 90-F1 antibody displayed the highest neutralizing capacity against MERS pseudovirus Erasmus strain andBisha 1 strain (FIG. 5a ,FIG. 5b and Table 2). Therefore, it was confirmed that 77-A5, 77-A6, 90-F1, and 90-F2 antibodies had a wide range of neutralizing capacity. - To investigate neutralizing capacity of the antibodies prepared in Example 1, plaque reduction neutralizing test (PRNT) was performed with MERS-CoV (Erasmus strain and KNIH strain). First, Vero cells were distributed in a 24-well plate at the density of 105 cells/well, followed by culture. The culture medium was discarded therefrom. The antibodies of Example 1 diluted in cell culture medium at the concentration of 10, 2.5, 0.625, 0.156, 0.039, 0.009, or 0.002 ng/m were mixed with the MERS-CoV (EMC, KNIH-002, KNIH-016, and KNIH-042 strains) diluted in 50 PFU/well, resulting in the preparation of a mixed solution. The mixed solution was added to the culture plate at the concentration of 100 μ/well, followed by reaction at 37° C. for 1 hour. Then, DMEM containing 1.5% CMC (carboxymethyl cellulose) was added to the plate at the concentration of 1 m/well, followed by culture for 3 days. Upon completion of the culture, plaques were observed by crystal violet staining. The number of plaques in each well was calculated, based on which neutralizing capacity was calculated by the following
mathematical formula 2. ND50 was also calculated by the followingmathematical formula 3 to calculate the neutralizing capacity. In themathematical formula 3, m indicates a log10 value of the highest rate of dilution, Δ indicates a constant interval between the rates of dilution expressed by a log10 value, and Σp indicates the average number of plaques for sum of all ratios of plaques/virus control. -
Neutralizing Capacity (%)=100−(plaque number of antibody-treated MERS virus/plaque number of antibody-non-treated MERS virus×100) [Mathematical Formula 2] -
log10 ND50 =m−Δ(Σp−0.5) [Mathematical Formula 3] -
TABLE 3 Neutralizing capacity of antibodies analyzed by PRNT Antibody ND50 ND50 antibody conc. (μg/ml) 77-A5 35.60 0.28 77-A6 95.73 0.10 90-A3 0.63 15.81 90-A9 0.58 17.30 90-B2 39.52 0.25 90-B7 14.93 0.67 90-C4 0.78 12.76 90-E5 6.60 1.51 90-E6 0.68 14.78 90-F1 956.46 0.01 90-F2 53.96 0.19 Negative Control 1.00 10.04 - As a result, as shown in
FIG. 6a ,FIG. 6b and Table 3, 77-A5, 77-A6, 90-B2, 90-B7, 90-F1, 90-F2, and 90-E5 antibodies demonstrated neutralizing capacity against MERS-CoV. Among them, 90-F1 antibody showed the highest neutralizing capacity (FIG. 6a ,FIG. 6b and Table 3). The results were the same for all MERS-CoV strains (EMC, KNIH-002, KNIH-016, and KNIH-042 strains). - The physicochemical characteristics of the antibodies 77-A5, 77-A6, 90-B2, 90-B7, 90-F1, and 90-F2, demonstrating excellent neutralizing capacity in Experimental Examples 2 and 3, were analyzed by SEC-HPLC (size exclusion chromatography-HPLC), SPR assay (surface plasmon resonance assay) and PTS assay (protein thermal shift assay).
- The antibody morphology was analyzed by using water SEC-HPLC system. Agilent Bio SEC3 was used as the HPLC column and ultraviolet absorption spectrophotometer (280 nm) was used as the detector. At this time, 10 μ of each antibody was loaded as the sample at the concentration of 1 mg/m. The flow rate was 0.3 m/min. 1×PBS was used as a moving phase for isocratic elution.
- As a result, as shown in
FIG. 7 , 6 kinds of antibodies were in the form of a certain monomer, and coagulation was not observed (FIG. 7 ). - The avidity of the antibodies was analyzed by SPR assay using S1 antigen or RBD antigen. Particularly, S1 antigen or RBD antigen was attached on the surface of CM5 chip, to which the antibody was loaded. The association time was 3 minutes and the dissociation time was as listed in Table 4. HBS-EP was used as a running buffer, and regeneration solution was as shown in Table 4 for SPR assay.
-
TABLE 4 SPR assay conditions Dissociation Antibody Time Regeneration Solution 77- A5 30 min. 10 mM NaOH, 1M NaCl 77- A6 6 min. 10 mM NaOH 90- B2 30 min. 10 mM NaOH, 1M NaCl 90- B7 10 min. 10 mM NaOH, 250 mM NaCl 90- F1 10 min. 10 mM glycine(pH 2.0), 250 mM NaCl 90- F2 6 min. 10 mM NaOH, 500 mM NaCl -
TABLE 5 Analysis of antibody avidity by SPR assay Characteristic 77-A5 77-A6 90-B2 90-B7 90-F1 90-F2 Avidity to S1 antigen Ka(1/Ms) 1.33 × 105 6.38 × 104 1.31 × 105 6.81 × 105 6.48 × 105 1.34 × 105 Kd(1/s) ≤1.00 × 10−5 4.43 × 10−5 ≤1.00 × 10−5 1.04 × 10−4 9.88 × 10−5 8.82 × 10−4 KD(M) ≤7.51 × 10−11 6.95 × 10−10 ≤7.51 × 10−11 1.53 × 10−10 1.53 × 10−10 6.60 × 10−9 Avidity to RBD antigen Ka(1/Ms) 1.30 × 105 4.67 × 104 — — 3.76 × 105 2.38 × 105 Kd(1/s) 2.08 × 10−5 3.15 × 10−5 — — 2.71 × 10−5 1.40 × 10−5 KD(M) 1.61 × 10−10 6.73 × 10−10 — — 7.20 × 10−11 5.86 × 10−9 - As a result, as shown in
FIG. 8a ,FIG. 8b and Table 5, the antibodies 77-A5 and 90-B2 attached with S1 antigen showed a high avidity to the S1 antigen, confirmed by the low Kr, value of up to 75 pM. The antibody 90-F1 attached with RBD antigen showed a high avidity to the RBD antigen, confirmed by the low KD value of up to 72 pM. In particular, 90-B2 and 90-B7 antibodies did not bind to the RBD antigen, indicating that the 90-B2 and 90-B7 antibodies were specific to the S1 antigen (FIG. 8a ,FIG. 8b and Table 5). - The antibody stability was investigated in PBS (phosphate buffered saline, pH 7.4) which included neither calcium nor magnesium. Particularly, 0.75 μg of each antibody prepared in Example 1 was used. PTS assay was performed by using Protein Thermal Shift™ Dye Kit (Catalog No. 4466038, Life technologies) according to the manufacturer's protocol.
- As a result, as shown in
FIG. 9a toFIG. 9c , the melting points of 77-A5, 77-A6, 90-B2, 90-B7, 90-F1, and 90-F2 antibodies were respectively 67.52° C., 68.44° C. and 75.44° C., 72.46° C., 68.21° C. and 81.19° C., 69.21° C. and 79.81° C., and 68.89° C. and 75.10° C. Therefore, all of the six antibodies were confirmed to have a stable structure because the protein hydrophobicity was exposed at the temperature of 67.52° C. or higher (FIG. 9a toFIG. 9c ). - Those skilled in the art will appreciate that the conceptions and specific embodiments disclosed in the foregoing description may be readily utilized as a basis for modifying or designing other embodiments for carrying out the same purposes of the present invention. Those skilled in the art will also appreciate that such equivalent embodiments do not depart from the spirit and scope of the invention as set forth in the appended claims.
Claims (28)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0106836 | 2017-08-23 | ||
KR1020170106836A KR101895228B1 (en) | 2017-08-23 | 2017-08-23 | Monoclonal antibody against spike protein of middle east respiratory syndrome coronavirus and uses therof |
PCT/KR2018/009754 WO2019039891A1 (en) | 2017-08-23 | 2018-08-23 | Monoclonal antibody for spike protein of middle east respiratory syndrome coronavirus, and use thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/009754 A-371-Of-International WO2019039891A1 (en) | 2017-08-23 | 2018-08-23 | Monoclonal antibody for spike protein of middle east respiratory syndrome coronavirus, and use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/952,308 Division US20230265169A1 (en) | 2017-08-23 | 2022-09-25 | Monoclonal antibody for spike protein of middle east respiratory syndrome coronavirus, and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210355193A1 true US20210355193A1 (en) | 2021-11-18 |
Family
ID=64100755
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/641,580 Abandoned US20210355193A1 (en) | 2017-08-23 | 2018-08-23 | Monoclonal anitbody for spike protein of middle east respiratory syndrome coronavirus and use thereof |
US17/952,308 Pending US20230265169A1 (en) | 2017-08-23 | 2022-09-25 | Monoclonal antibody for spike protein of middle east respiratory syndrome coronavirus, and use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/952,308 Pending US20230265169A1 (en) | 2017-08-23 | 2022-09-25 | Monoclonal antibody for spike protein of middle east respiratory syndrome coronavirus, and use thereof |
Country Status (3)
Country | Link |
---|---|
US (2) | US20210355193A1 (en) |
KR (1) | KR101895228B1 (en) |
WO (1) | WO2019039891A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102007161B1 (en) * | 2018-11-07 | 2019-08-07 | 대한민국 | Monoclonal antibodies of specifically binding to spike S1 protein of MERS-CoV |
KR101969696B1 (en) * | 2019-01-23 | 2019-04-16 | 대한민국(관리부서 질병관리본부장) | Monoclonal antibodies of specifically binding to spike S2 protein of MERS-CoV |
US11168128B2 (en) | 2020-02-26 | 2021-11-09 | Vir Biotechnology, Inc. | Antibodies against SARS-CoV-2 and methods of using the same |
WO2021221493A1 (en) * | 2020-04-29 | 2021-11-04 | 한국화학연구원 | Sars coronavirus 2 diagnostic kit including receptor and antibody binding to sars coronavirus 2 spike protein |
KR102351653B1 (en) * | 2020-04-29 | 2022-01-14 | 한국화학연구원 | Diagonstic kits for SARS coronavirus 2 comprising the receptor and the antibody binding to SARS coronavirus 2 spike protein |
CN113667010B (en) * | 2020-05-15 | 2023-07-28 | 普米斯生物技术(珠海)有限公司 | Antibody against coronavirus and use of derivative thereof |
MX2022016215A (en) * | 2020-06-15 | 2023-05-30 | Neuome Peptides Pte Ltd | Lateral flow assay device for detection of analytes and method of detection thereof. |
BR112023000503A2 (en) * | 2020-07-16 | 2023-01-31 | Caregen Co Ltd | PEPTIDE WITH NEUTRALIZING ACTIVITY AGAINST CORONAVIRUS-2 SEVERE ACUTE RESPIRATORY SYNDROME |
EP4186922A1 (en) * | 2020-07-24 | 2023-05-31 | Celltrion, Inc. | Binding molecule having neutralizing activity against coronavirus superfamily |
KR20220026083A (en) | 2020-08-25 | 2022-03-04 | 바이오스트림테크놀러지스(주) | Fusion protein comprising of immunoglobulin constant region and receptor-binding domain of coronavirus |
CN114426574A (en) * | 2020-10-29 | 2022-05-03 | 中国科学院武汉病毒研究所 | Novel coronavirus neutralizing human monoclonal antibody and application thereof |
WO2022098173A1 (en) * | 2020-11-06 | 2022-05-12 | 주식회사 녹십자 | Antibody specific to coronavirus spike protein and use thereof |
CN112442120A (en) * | 2020-11-25 | 2021-03-05 | 苏州大学 | Neutralizing antibody against SARS-COV-2 of severe acute respiratory syndrome type II coronavirus |
CN114605527B (en) * | 2020-12-04 | 2023-07-04 | 中国科学院分子细胞科学卓越创新中心 | Antibody for resisting novel coronavirus SARS-CoV-2 and its preparation method and use |
CN117487004B (en) * | 2023-09-25 | 2024-04-30 | 中山大学 | Monoclonal antibody against coronavirus S protein and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2922258C (en) * | 2013-09-19 | 2022-11-29 | Novavax, Inc. | Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods |
WO2015057942A1 (en) * | 2013-10-18 | 2015-04-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (mers-cov) and engineered bispecific fusions with inhibitory peptides |
JO3701B1 (en) * | 2014-05-23 | 2021-01-31 | Regeneron Pharma | Human antibodies to middle east respiratory syndrome – coronavirus spike protein |
-
2017
- 2017-08-23 KR KR1020170106836A patent/KR101895228B1/en active
-
2018
- 2018-08-23 WO PCT/KR2018/009754 patent/WO2019039891A1/en active Application Filing
- 2018-08-23 US US16/641,580 patent/US20210355193A1/en not_active Abandoned
-
2022
- 2022-09-25 US US17/952,308 patent/US20230265169A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019039891A1 (en) | 2019-02-28 |
US20230265169A1 (en) | 2023-08-24 |
KR101895228B1 (en) | 2018-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230265169A1 (en) | Monoclonal antibody for spike protein of middle east respiratory syndrome coronavirus, and use thereof | |
JP7077377B2 (en) | Oncolytic virus for expression of immune checkpoint modulator | |
US20220169733A1 (en) | Immunological Reagents | |
JP6949713B2 (en) | Anti-lymphocyte activation gene 3 (LAG-3) antibody | |
JP6843736B2 (en) | Combination of oncolytic virus and immune checkpoint modulator | |
EP2793940B1 (en) | Surrogate binding proteins | |
Benoit et al. | A monoclonal antibody to recombinant human IFN-alpha receptor inhibits biologic activity of several species of human IFN-alpha, IFN-beta, and IFN-omega. Detection of heterogeneity of the cellular type I IFN receptor. | |
CN109306014B (en) | Intercortin-targeted chimeric antigen receptor modified T cell and application thereof | |
US20180265582A1 (en) | Immunological Reagents | |
KR102332847B1 (en) | Antibodies Against T cell Immunoreceptor with Ig and Tyrosine-Based Inhibitory Motif Domains and Uses Thereof | |
CN106589116B (en) | Flavivirus human monoclonal antibody and application thereof | |
CN108884149A (en) | HIV-1 GP41 neutralizing antibody and application thereof | |
WO2016021864A1 (en) | Human antibody specific to c-met and preparation method therefor | |
KR20180016321A (en) | Antibodies Against Programmed death-ligand 1 and Uses Thereof | |
US20230348880A1 (en) | Soluble ace2 and fusion protein, and applications thereof | |
US20170166642A1 (en) | Immunological Reagents | |
US20210253713A1 (en) | Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use | |
WO2021231466A2 (en) | Ace2 compositions and methods | |
KR20210025071A (en) | CD226 agonist antibody | |
JP6716544B2 (en) | Treatment and functional cure of HIV infection with a monoclonal antibody against CD4 that mediates competitive HIV entry inhibition | |
CN112912398A (en) | Novel antibodies and nucleotide sequences and uses thereof | |
CN116323954A (en) | Oncolytic viruses expressing immunomodulatory fusion proteins | |
WO2024008126A1 (en) | Il2 muteins and uses thereof | |
CN112538117B (en) | Anti-human carcinoembryonic antigen antibody and coding gene and application thereof | |
WO2021238910A1 (en) | Anti-coronavirus spike protein antibodies and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNITED STATES GOVERNMENT AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WANG, LINGSHU;GRAHAM, BARNEY S.;MASCOLA, JOHN R.;SIGNING DATES FROM 20210824 TO 20210827;REEL/FRAME:057619/0946 Owner name: KOREA (CENTER FOR DISEASE CONTROL AND PREVENTION), KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEE, HANSAEM;CHOI, JANGHOON;KIM, SUNGSOON;REEL/FRAME:057619/0832 Effective date: 20210830 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, MARYLAND Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ERROR IN THE ASSIGNEE'S NAME TO CORRECTLY REFERENCE THE ASSIGNEE AS LISTED ON THE ASSIGNMENT PREVIOUSLY RECORDED AT REEL: 057619 FRAME: 0946. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:WANG, LINGSHU;GRAHAM, BARNEY S;MASCOLA, JOHN R;SIGNING DATES FROM 20210824 TO 20210827;REEL/FRAME:059716/0021 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |